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Voltage-gated K+ Channels and HIV-1-induced Neural Injury: Implications for
Pathogenesis of HIV-1-associated Neurocognitive Disorders
Han Liu, Ph.D.
University of Nebraska Medical Center, 2016
Supervisor: Huangui Xiong, M.D., Ph.D.
Human immunodeficiency virus-1 (HIV-1)-associated neurocognitive disorder (HAND)
is a subcortical disease involving neuronal loss and myelin damage. Myelin is deposited
by oligodendrocytes through a complex process including oligodendrocyte progenitor
cell (OPC) proliferation and maturation. Oligodendrocytes/OPCs are susceptible to viral
proteins such as Tat and that myelin damage is associated with oligodendrocyte number
decrease. It has been shown that activation of voltage-gated K+ (KV) channels mediates
apoptosis in various cell types. KV1.3 is the most predominant KV channel expressed in
OPCs/oligodendrocytes and potentially involved in OPC developmental regulation. We
studied the involvement of KV1.3 in Tat-induced OPC/oligodendrocyte injury and OPC
maturation deficit. Tat increased KV1.3 currents in cultured OPCs and oligodendrocytes
may through direct interaction and interrupting channel phosphorylating regulation,
leading to OPC maturation retardation and OPC/oligodendrocyte apoptosis. Tat-caused
myelin injury was validated in corpus callosum and striatum of cultured rat brain slices.
These effects were prevented by KV1.3 antagonists or KV1.3-siRNA knockdown.
Gelsolin (GSN), an actin-binding protein best-known for its modulation of cell motility
and secretion. Neurons appear to be a major source of GSN in CNS and GSN-null
neurons have enhanced cell death. The GSN level is decreased in CSF of HIV-1infected individuals. Studies have demonstrated that enhancement of KV currents results
in neuronal apoptosis. To understand how the decreased level of GSN causes neuronal
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injury in HAND, we studied the effects of GSN on HIV-1 glycoprotein 120 (gp120)activated outward K+ currents in primary rat cortical neuronal cultures. Gp120 enhanced
outward K+ and resulted in neuronal apoptosis. GSN suppressed the gp120-induced
outward K+ current increase and reduced vulnerability to gp120-induced neuronal
apoptosis. The GSN-mediated suppression of gp120 enhancement of neuronal outward
K+ current was blocked by KV2.1 inhibitor. In parallel, gp120 up-regulated KV2.1 channel
expression, which was also blocked by GSN.
Taken together, my thesis research demonstrates that Tat induces myelin damage
by KV1.3-mediated OPC/oligodendrocyte injury and maturation defects, which may have
implications for the pathogenesis of HAND. GSN protects neurons from gp120associated changes by suppression of gp120-induced enhancement of KV2.1 K+ currents,
which may reflect a neuroprotective role of GSN in HIV-1-infected brain.
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Chapter 1 Introduction

Review of HIV-1-associated Neurocognitive
disorder, neurons, oligodendrocyte, and K+
channels in HIV-1-associated
neuropathogenesis
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Abstract
Oligodendrocytes wrap neuronal axons to form myelin, which is an insulating sheath
essential for the electrical saltatory conduction along axons. The process of myelination
is highly regulated by neuronal and astrocytic signals and, maintenance of myelin
sheaths is a very complex process. Oligodendrocyte injury results in demyelination and
further neurological dysfunction. Demyelination in cerebrum may cause cognitive
impairment in a broad array of diseases including human immunodeficiency virus type
one (HIV-1)-associated neurocognitive disorder (HAND). Although the combined
antiretroviral therapy has markedly reduced HIV-1 incidence of HIV-1-associated
dementia, which is a severe form of HAND, milder forms of HAND remain prevalent
even when viral load in blood is well controlled. HAND manifests as a subcortical
dementia involving subcortical damage in white matter (e.g., corpus callosum), which
mostly consists of myelinated axonal fibers. How HIV-1 brain infection causes myelin
injury and resultant white matter damage is an interesting area of current HIV-1
neurology research. In this Chapter, we tentatively address recent progresses on
oligodendrocyte dysregulation and HAND pathogenesis.
Key words: HIV-1, dementia, oligodendrocyte, myelin sheath
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Although combination antiretroviral therapy (cART) has markedly reduced human
immunodeficiency virus type one (HIV-1)-associated mortality, HIV-1-associated
neurocognitive disorders (HAND) remains prevalent [1-3]. More than 50% of HIV-1
positive individuals have central nervous system (CNS) syndromes, involving subcortical
damage in white matter (WM, e.g., corpus callosum) and/or deep grey matter [4-8]. HIV1-related WM damage includes demyelination and axonal dysfunction and/or damage.
Demyelination is when myelin sheath of neuronal axons, which enables rapid and
efficient saltatory conduction, is impaired in the CNS or peripheral nervous system
(PNS). Myelination, formation of myelin sheaths by oligodendrocytes wrapping neuronal
axons in the CNS or Schwann cells in the PNS, is highly regulated by neuronal and
astrocytic signals and, maintenance of myelin sheaths is a very complex process.
Oligodendrocyte injury is the hallmarks of demyelination and WM damage.
Oligodendrocyte injury can be induced by genetics, viral proteins, inflammation,
autoimmune response and other unknown factors. HIV-1-related oligodendrocyte/myelin
injury has been reported both in cell culture [9] and patients [10].
Earlier studies demonstrate that human polyomavirus JC (JCV) primarily causes
demyelination in HIV-1-infected brain. Compared to HIV-1 infection of astrocytes and
microglia in brain, JCV predominately infects oligodendrocytes and thus cause
oligodendrocyte loss and demyelination. JCV is the main causative of progressive
multifocal leukoencephalopathy (PML), a frequent opportunistic infection in the CNS and
a common complication seen in AIDS patients [10, 11]. Recently, several research
groups have reported that HIV-1 and viral proteins per se can target at oligodendrocytes
and cause the detrimental effects, which are JCV-independent [9, 12, 13]. HIV-1 viral
proteins, including the envelope glycoprotein gp120, trans-activator of transcription (Tat),
and negative regulatory factor (Nef), have been implicated in oligodendrocyte toxicity [12,
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14-17]. Among these proteins, Tat has been detected in both infected and uninfected
oligodendrocytes in the brains of AIDS patients [10], and showed synergistic effect with
JCV or addictive drug as morphine. The myelin injury-related milder neurocognitive
disorders and the oligodendrocyte pathogenesis in HAND are attracting attention of
neurovirologists worldwide.
1. Overview of HAND
HIV includes two types, HIV type 1 and 2 (HIV-1, 2). There is limited knowledge
about HIV-2, which has not been commonly seen outside of Africa. Thus all of the
diseases mentioned in this dissertation are HIV-1 associated. HIV-1 primarily infects
CD4+ T cells and monocyte/macrophage lineage cells. HIV enters cells by interacting
with CD4 receptor and two co-receptors, CXCR4 or CCR5.
Infected monocytes or macrophages traverse blood brain barrier (BBB) to invade
brain. The invasion of HIV-1 happens in the early stage of primary infection. Invaded
viruses replicate in brain, causing inflammatory and neurotoxic effects that contribute to
cognitive, behavioral and motor function deficits. This progressive neurologic disease is
clinically characterized by cognitive deficits in patients with HIV-1 infection [18].
1.1. HAND clinical diagnosis
HAND is divided to three categories depending on degree of severity: asymptomatic
neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-1associated dementia (HAD). The detailed current diagnostic criteria for HAND are
published on AIDS education and Training Centers National Coordinating Resource
Center

(http://aidsetc.org/guide/hiv-associated-neurocognitive-disorders).

Patients

accept standardized neuropsychological survey (e.g. learning function, construction,
memory registration, attention, concentration) and are diagnosed by a combination of
dementia scale, day-to-day functioning interference, and no pre-existing cause of
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cognitive deficits [1, 19-21]. However, the impairments in ANI and MND may escape
clinical diagnosis. HAD patients undergo marked neuron interference with daily
functioning, acquire cognitive impairments particularly in the new information registration,
information processing and attention/concentration deficits [20-22].
1.2. Overview of HAND neuropathogenesis
Obviously, HAND symptoms are closely attribute to neuronal dysfunction or/and loss.
However, HIV-1 does not infect neurons directly. The mainly proposed mechanisms
leading to HAND involve infected macrophages, microglia, or astrocytes secreting
neurotoxins resultant in neuronal function alterations and death. Viral proteins (e.g.
gp120, Tat, Nef, Vpr), arachidonic acid, free radicals (NO. and O2.-), glutamate,
quinolinate, cysteine, cytokines (e.g., CCL12, IL-1β, TNF-α), and amines have been
reported that act as neurotoxins in HAND [23]. These toxic factors generally act through
two proposed models: direct model and indirect model. The direct model offers
hypothesis that viral proteins released from infected cells manifest direct cytotoxicity on
neurons [24]. The indirect model proposes that the neuronal death or dysfunction is
consequently mediated by inflammatory response designedly against HIV-1 infection or
viral proteins [24, 25]. The HIV-1 infection-caused processes alter neuronal function and
survivals have been extensively addressed. In the pre-cART era, inflammation and
neurodegeneration were believed as the predominant pathogenesis drive HAND
progression [26]. However, emerging evidences demonstrate the direct actions of viral
proteins may take the major place particularly in these patients with good access of
cART [27, 28].
2. Overview of oligodendrocytes
In the CNS, oligodendrocyte plasma membrane processes enclose axons leading to
formation of myelin sheath, which is essential for fast axonal conduction. Myelinated
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axons appear myelin-dependency during development, thus demyelination can lead to
progressive decline in these axons [29]. Neuronal conduction deficits in HAND patients
can be attribute to primary neuron injury or consequent injury caused by myelin
dysfunction/loss, suggesting disruption of oligodendrocyte function my contribute to
HAND progression [27]. Oligodendrocytes rise from oligodendrocyte progenitor cells
(OPCs) or neural stem/progenitor cells (NPCs). These two populations are capable to
generate new oligodendrocytes in response to myelin injury to maintain myelin function.
[30]. As OPCs are the major proliferating cell population within the adult CNS, they have
the most capacity to re-form myelin sheath. Thus, OPC proliferation, differentiation and
maturation are critical processes for axonal remyelination. It has been shown that
differentiation of OPCs into oligodendrocyte is greatly challenging during remyelination
[31, 32]. OPC differentiation is controlled by a number of factors, many of which act to
inhibit myelination, including Leucine-rich repeat and immunoglobulin domaincontaining-1 (LINGO-1) [33, 34], Notch-1 [35, 36], Wnt [37] etc. Whereas, p38 MAPK [38,
39] and AKT [40] have been shown to be required for oligodendrocyte differentiation and
myelination.
3. Myelin/oligodendrocyte injury in HIV-1 patients
The oligodendrocyte and myelin injury have been observed clinically from
neurological imaging studies, serum biochemistry and brain biopsies [6, 8, 41, 42]. The
diffusion tensor magnetic resonance imaging (DTI) promotes the investigations of WM
damage in early HAND and, allows revealing the microstructures of myelin and
oligodendrocytes. The changes of water molecules diffusive parameters in brain WM of
HIV-1 patient, which indicate demyelination, have been detected in several DTI studies
[6, 43, 44]. These findings were supported by a recent study in HIV-1-infected
humanized mice that the decreased expression myelin structural proteins were observed
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in whisker barrels, corpus callosum, and hippocampus, suggesting the loss of myelin
elements [45]. In the serum and CSF of patients with HAND, antibody titers of myelin
oligodendrocyte glycoprotein (MOG), an important myelin structural protein indicating
CNS-specific autoimmune reaction for primary demyelination, are significantly higher
compared with asymptomatic HAND patients and HIV-1-negative patients with other
neurological disease. In particular, CSF anti-MOG antibodies exhibit a high sensitivity
and specificity (85.7% and 76.2%) in those patients with active HAND. The
performances on HIV dementia scale test are significantly worse and the viral loads in
CSF are higher in MOG immunopositive HAND patients than those in asymptomatic
HAND patients [46], suggesting the dysfunction of oligodendrocyte is closely related with
HIV-1 infection and HAND.
Compared to astrocytes that tend to promote recovery in response to injury,
oligodendrocytes are more susceptible and appear to be damaged as a general
response to insults [47]. In biopsy studies, the significant loss of nerve fibers and axons
are observed in HIV-1-infected brain, in particular in the frontal and occipital parts of the
corpus callosum. The myelin sheath thickness diminishes in corpus callosum as well [8].
Weighted gene co-expression network analysis showed an increase of oligodendrocyterelated genes particularly in the HIV encephalitis (HIVE) group, suggesting specific
dysfunction of oligodendrocyte in HIVE [48].
In those HIV-1 positive patients with PML, the myelin loss is apparent both
macroscopically and microscopically [49]. Neuroimaging studies show the myelin lesions
are more frequently seen in the sub-cortical WM areas [50]. PML is believed to be
developed exclusively in immunosuppressive patients with significantly higher incidence
in patients with AIDS, particularly in AIDS patients without cART and with a low
lymphocyte CD4+ count, than in patients with any other immunosuppressive conditions.
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Although cART has decreased the incidence of PML and improved the patient survival
[51], PML was recently reported that occurred in HIV-1-positive patients with good
access of cART and even with normal CD4+ lymphocyte level [52, 53]. These findings
suggest PML-related oligodendrocyte/myelin damage is often, but not necessarily,
associated with severe immunosuppression or an immune reconstitution inflammatory
syndrome (IRIS) in pathogenesis of cART era HIV neurology (neuroHIV) [54].
4. Fate of oligodendrocytes in HIV-1-infected brain
Early publications reported that HIV-1 cannot be detected in oligodendrocytes [55,
56], may due to the limitations of methodology to identify oligodendrocytes. Dissenting
result was found in purified human oligodendrocytes from temporal lobe resections, HIV1 (IIIB and BaL) infectivity was confirmed by detection of p24gag antigen and PCR
amplification [57]. It is well-known that HIV-1 attaches and infects human host cells
through CD4 receptor, along with CXCR4 and CCR5 as co-receptors. Oligodendrocytes
are CD4 and CCR5 negative but do express CXCR4 [28, 55, 58], which designedly
promote the OPC migration and remyelination [59], may provide the anchor for HIV-1induced oligodendrocyte toxicity. However, most investigators agree that HIV-1 primarily
infects microglial cells of the brain but oligodendrocyte is not the main target. HIV-1associated oligodendrocyte injury is believed to be mediated through viral proteins shed
from viruses released from infected other cells [12, 14, 15].
In HIV-1 patients with PML complication, Tat and JCV are both present in
oligodendrocytes. Tat has been shown to synergize with JCV, and facilitate of JCV gene
transcription and replication, leading to robust JCV infection [60, 61]. Tat stimulates JCV
gene transcription by cooperating with SMAD proteins, the intracellular effectors of TGFbeta, at the JCV DNA control region (Fig. 1A) [60]. The effectiveness of Tat on
facilitating JCV transcription and replication varies from different HIV clades [61].
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Because Tat can continuously exist in brain while the viral load is controlled in blood, this
may partially explain the cases that HIV-1 patients develop PML even with good access
of cART [62]. Besides the synergistic effect of Tat and JCV in oligodendrocytes,
cytotoxic CD8+ T cells aggregate at demyelinated lesions in brain to engage JCVinfected oligodendrocytes, which tends to control JCV dissemination but at the cost of
oligodendrocyte death and further demyelination in PML [63].
In

addition

to

Tat,

gp120

seems

to

involve

in

HIV-1-associated

oligodendrocytes/myelin injury as well. It has been shown that gp120 inhibits myelination
in rat cerebral cortex culture [14] and to induce functional dysregulation and apoptosis in
cultured oligodendrocytes [15, 64], which is discussed in subsequent section. The
primary oligodendrocyte injury, which leads to secondary axonal injury (outside-in) to
further exacerbate neurocognitive impairments, oligodendrocyte injury can be caused by
primary axonopathy as well (inside-out) [65]. The recent study has shown that gp120induced β-APP accumulation and axon injury in corpus callosum was attenuated by a
CXCR4 antagonist, exampling HIV-1 injury of oligodendrocyte/myelin injury via CXCR4
receptors [28]. Although it is not clear whether gp120 cause such a detrimental effect
through “outside-in” or “inside-out” mechanism or both, CXCR4 expressed on
oligodendrocytes can be a potential target [65].
5. Association between BBB disruption and myelin deficits
Increasing evidences indicate that myelin injury may be associated with dysregulated
BBB since WM pallor is often observed in perivascular sectors [66] [67]. BBB is a
critically protective barrier for the brain. It serves as a highly selective layer that separate
CNS from the rest of the body. HIV-1-related BBB alteration is attributed to
proinflammatory cytokine secretion, released viral proteins from infected cells, and HIV-1
infection of endothelial cells [68, 69]. The reported direct mechanisms are often related
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to alterations of vascular tight junctions, direct toxicity of brain endothelial cells,
production of matrix metalloproteinase, and NMDA receptor activation [70, 71]. The
disruption of BBB is believed essential for HIV-1 to access to brain. In another hand,
BBB alteration per se may also underlie neurologic deficits in neuroHIV patients. This is
supported by an observation that HIV-1 patients with impaired BBB showed poorer
neurologic status than those with intact BBB [72]. However, myelin damage may be
related to BBB disruption without HIV-1 brain invasion. In a case report, diffuse myelin
pallor in WM and massive perivascular dilatation were observed in an AIDS patient
without evidence of brain HIV infection, significant inflammation, or microglial activation
[73]. Postmortem studies on AIDS patients brains showed that the discrete myelin pallor
areas are always associated with capillaries or venules [67]. These findings suggest that
BBB breakdown caused diffuse leak and other circulating factors may contribute to the
observed myelin pathogenesis.
Under physiological conditions, the BBB endothelial cells and components of the
extracellular matrix support OPC survival, and promote NPC differentiate to neurons,
astrocytes and oligodendrocytes [74-76]. The critical function of BBB and the
consequences of BBB alteration imply the contributions of BBB disruption in HIV-1associtated oligodendrocyte/myelin injury. It is not surprising the BBB disruption will
result in enhanced entrance of free virus, infected T cells, and toxic components from
blood. It has been reported that OPC proliferation can be reduced by plasma, serum,
thrombin and plasmin in primary culture. Thrombin also suppresses the differentiation of
OPCs into mature oligodendrocytes [77]. In addition, the expression level of TNF-α is
elevated in blood mononuclear cells of HIV-infected patients [78], of which TNF-α is
demonstrated that promoting oligodendrocyte death [79]. HIV-1 infection also induces
interleukin (IL)-1β production in human monocytes [80], of which IL-1β can promote
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oligodendrocyte death through glutamate excitotoxicity [81]. These findings provide
potential

mechanisms

of

BBB

disruption

contribution

to

HIV-1-associated

myelin/oligodendrocyte damage.
6. Cellular mechanisms of oligodendrocyte loss in HIV-1-infected brain
Apoptosis of oligodendrocytes has been demonstrated in HAND patients.
Accumulating evidences indicate that HIV-1 viral proteins can injure oligodendrocytes
directly or through a comorbid effect with addictive drugs.
It is well-known that tumor suppressor p53 induce apoptosis by activating
transcription of various pro-apoptotic genes [82]. Activation of p53 is detected in the
oligodendrocyte lineage cells in the brain of HAND patients, which cannot be detected in
control brains [83]. Because of difficulties to distinguish differentiating stages of
oligodendrocyte lineage on autopsy samples, the detected p53 reactivity reflects
apoptosis of mature oligodendrocytes (Fig. 1B) and OPCs. This suggests that in addition
to oligodendrocyte injury, proliferation of OPCs may be also impaired in HAND.
Gp120 causes slow but progressive oligodendrocyte cytosolic Ca2+ rise in a mixed
culture of cerebellar cortex cells [64], which is a potential apoptotic cause. Exposure of
oligodendrocytes to Tat also triggers rapid increase in intracellular Ca2+ level through
targeting at NMDA and AMPA receptors thus cause consequent oligodendrocyte injury.
It is worth to mention that the roles of NMDA and AMPA receptors appear to be different
and dependent on the stage of OPC differentiation [9]. Our data suggest that Tat can
cause oligodendrocyte apoptosis in vitro and myelin loss ex vivo by enhancing voltagedependent K+ channel (KV) 1.3 activity (Chapter 2). The efflux of K+ ions causes the cell
shrinkage leading to apoptotic cell volume decrease and eventual apoptosis (Fig. 1B)
[84]. Oligodendrocytes within the striatum are highly sensitive to the effects of morphine
in HIV-1 Tat transgenic mice [12]. Striatal oligodendrocytes are the only apoptotic cell
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type in response to combined morphine exposure and Tat induction in the Tat transgenic
mice [12]. Tat also interacts with morphine to decrease the proliferation of OPCs [85].
Opioid abuse causes synergistic toxicity in HIV-1-associated pathogenesis by direct
actions on immature astrocytes and oligodendrocytes which express µ-opioid or κ-opioid
receptors [86].
In other virus-induced demyelination, there is clear evidence that mouse hepatitis
virus can directly infect and activate microglia during acute inflammation which
eventually causes phagocytosis of myelin sheath and thus leading to demyelination
during chronic inflammation stage [87]. Similar theory has been well established in
multiple sclerosis, which is the most prevalent demyelinating disease, that immuneactivated microglia strip the myelin. Recent evidences show that microglia appear to be
more phagocytotic in response to HIV-1 Tat and result in neuronal loss [88, 89].
Although there is no direct evidence indicating microglia phagocytosis of oligodendrocyte
in neuroHIV [54], it is likely that the infected and activated microglia can also phagocyte
oligodendrocytes and myelin sheath, leading to the myelin damage and consequent
HAND pathogenesis.

7. Myelin maintenance and remyelination in HIV-1-infected brain
Repair of the damaged myelin sheath, which is called remyelination, is
physiologically required to maintain the myelin homeostasis. The myelin injury in
neuroHIV may also be induced by abnormalities of remyelination, in addition to loss of
existing myelin sheath. Remyelination requires proliferation and survival of OPCs,
migration of OPCs to the local lesion site, development from immature oligodendrocytes
to myelinating mature oligodendrocytes. The alterations of OPC regulating signals
related to remyelination process are found in HIV-1.
7.1. Altered OPC proliferation and differentiation in HIV-1-infected brain
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In HIV-1-infected brain, mild myelin damage is associated with an increase in
oligodendrocyte number, but the number decrease in severe myelin damage [90]. In an
agreement with the aforementioned results, mRNA levels of transcription factor Olig2, a
marker expressed with higher levels in OPC and lower levels in mature oligodendrocytes
[91], are elevated in the front cortex of patient with HIVE [48], indicating an increase of
OPC

proliferation

is

needed

for

repairing

damaged

myelin

sheath.

Mature

oligodendrocytes defect is also observed in animal model of secondary degeneration,
which represents additional loss of neurons, myelin, and glial cells through toxic events.
Early onset of secondary degeneration triggers OPC proliferation, but the cell numbers
decrease in a long-term [31]. However, Tat exposure reduces the population of
undifferentiated Sox2+ NPC (ancestor of OPC) and Olig2+ OPCs, but progenitor survival
is unaffected [85], suggesting the proliferation was interrupted. Tat may inhibit NPC
proliferation by down-regulating cyclin D1, which is an important cell cycle component
interacts with cyclin dependent kinase 4 and 6 [92] (Fig. 1C). Over all, HIV-1 infection or
viral protein exposure tends to incline NPC fate toward generation of astroglia cells at
the expense of neurons and/or oligodendrocytes [85, 93, 94]. Thus we consider OPC
differentiation and maturation are likely to be the key point for remyelination in neuroHIV.
7.2. Imbalance of OPC differentiation and remyelination in HIV-1-infected brain
It has been shown that differentiation of OPCs into post-mitotic oligodendrocytes is a
major check-point in the myelination process. As mentioned in Section 2,
oligodendrocyte differentiation is controlled by various factors, which are most negative
mediators. While molecular mechanisms in the regulation of developmental myelination
are discussed in excellent review papers published elsewhere [95, 96], the direct
interaction between HIV-1 and these molecules remains largely unknown. It is, however,
believed that HIV-1 may disturb the complex regulating network leading to the
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remyelination imbalance based on the following findings: 1) HIV-1 alters cell cycle by
Wnt signaling pathways and further impact the cell proliferation and differentiation in
different cell types, including peripheral blood mononuclear cells [97], HEK293 cells [98],
and astrocytes [99]. 2) HIV-1 infection of primary-derived astrocytes altered astrocyte
Wnt profile by elevating Wnt family members 2b and 10b [99]. 3) Elevation of secreted
Wnt signal from astrocytes may negatively regulate oligodendrocyte differentiation in
neuroHIV (Fig. 1C). 4) Notch-1 signaling is permissive for OPC expansion but inhibit
differentiation and myelin formation [100]. 5) In Kaposi`s sarcoma cells, which is a
neoplasm in HIV-1-infected individuals, overexpression of activated Notch-1 signaling is
detected [101]. However, to our knowledge, there is no yet report on how
OPC/oligodendrocyte

Notch-1

signaling

in

responding

to

HIV-1.

Moreover,

overexpression of CD44, a predominant hyaluronan receptor widely expressed in
nervous system, on precursor cells inhibits differentiation toward oligodendrocytes and
promotes differentiation into astrocytes, thus plays a negative role in OPC differentiation
and myelination [102, 103]. In lymphocyte cell lines of Jurkat and U937 cells, HIV-1
infection-caused particle production is accompanied by CD44 up-regulation [104]. In
HIV-1-related diffuse large B-cell lymphoma patients, the CD44 levels significantly
increased compared with HIV-1-unrelated diffuse large B-cell lymphoma patients (87%
vs. 56%) [105]. These findings suggest CD44 may play a role in HIV-1-related
remyelination failure.

Neurotrophins are important factors in the regulation of oligodendrocyte myelination
and remyelination. The main cellular sources for neurotrophins in brain are astrocytes,
microglial cells, and neurons, in addition to contribution of lymphocytes through the
blood circulation. Being aware of excellent reviews on the alteration of neurotrophins in
HAND [106] and immunological communications between oligodendrocytes and
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microglia [107], we here focus on the HIV-1-induced alterations of neurotrophins that
potentially associate with oligodendrocyte abnormalities.

The platelet-derived growth factor (PDGF) is the most predominant mitogen for
oligodendrocyte lineage cells. PDGF A and B chain both promote proliferation through
activating PDGF receptor alpha (PDGFRα) expressed on OPCs, whereas the PDGF B
chain appears to be more important for early NPC expansion [108, 109]. It has been
shown that PDGF regulates OPC development via glycogen synthase kinase-3β (GSK3β) signaling pathway, which is a negative regulator of OPC differentiation and
remyelination [110, 111]. PDGF-BB prevents NPC from Tat-mediated proliferating
impairment by inactivating GSK-3β/β-catenin pathways and, this effect is significantly
inhibited by the p38 and JNK inhibitors [112]. The levels of fibroblast growth factor (FGF),
which is an important pro-survival signal to stimulate OPC proliferation [113], increased
in the sera of HIV-1-infected patients [114, 115], but decreased in CSF [115]. FGF
signaling complex is interrupted in HIV-1-infected brain, results in the abnormal
activation of downstream signals including GSK-3β [116, 117], p38, ERK, and JNK
cascades [118] in neurons through the surface receptors such as NMDA receptor and
CXCR4, which are also expressed on oligodendrocytes [59, 119, 120]. In addition, HIV-1
Tat and FGF-2 share a common core mechanism of unconventional secretion [121],
although it is not clear whether they compete for the secretory routine. The brain-derived
neurotrophic factor (BDNF), predominantly derived from astrocytes, has also been found
to be essential for oligodendrocyte lineage development [122-125]. In rat primary
neurons, gp120 promotes a time-dependent proBDNF accumulation at both intracellular
and extracellular spaces by decreasing the expression level of intracellular furin, an
enzyme required for cleavage and release mature BDNF, leading to a reduction in
mature BDNF (Fig. 1C). A similar imbalance in the ratio of proBDNF/mature BDNF was
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confirmed in postmortem brains of HAND patients [126]. These findings suggest that
HIV-1 decreases the brain BDNF level by infecting astrocytes and gp120-associated
neurotoxicity, resulting in down-regulated remyelination. As BDNF is believed to protect
neurons from HIV-1-induced apoptosis, thus the reduction of BDNF may also make the
oligodendrocyte losing the support from neuronal axons that consequently cause myelin
damage through “inside-out” mechanism as proposed [65].

Besides these signaling molecules, HIV-1 Tat interacting protein (TIP30), a co-factor
that specifically enhances HIV-1 Tat-activated transcription [127], negatively regulates
oligodendrocyte development. Overexpression of TIP30 dramatically inhibits the OPC
differentiating progression, while knockdown of TIP30 enhances the differentiation of
OPC remarkably [128]. Blockade of TIP30 may have dual benefits on inhibiting Tatdependent genes transcription and promoting OPC differentiation, which is a potential
therapeutic strategy on HIV-associated demyelination. Ion channels are also involved in
regulation of OPC development. Kv1.3 [129, 130], Kv1.6 [129], inward rectified K+
channel 4.1 [131, 132] play crucial roles in regulation of OPC/oligodendrocyte
proliferation and differentiation. Generally, channels expressions on oligodendrocyte
lineage cells correlate with differentiating stages and the correlations are more complex
in OPCs than in oligodendrocytes. Particularly, Kv1.3 channel plays a crucial role in
G1/S transition in proliferating OPCs through regulating AKT signaling [130, 133].
Moreover, L-type voltage-operated Ca2+ channel 1.2 knockdown induces a decrease in
the proportion of oligodendrocytes expressing myelin proteins, and an increase in the
population of immature oligodendrocyte [134].

Very recent study proposed that myelin injury in HAND is partially due to effects of
antiretroviral drugs on oligodendrocyte survival and differentiation. The common
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prescribed antiretroviral drugs, ritonavir and lopinavir, impair both the differentiation of
OPCs into myelin-producing oligodendrocytes and the maintenance of myelin proteins in
vivo. Ritonavir induces accumulation of reactive oxygen species, which arrest
oligodendrocyte differentiation process [135, 136]. Controversial results were reported in
HIV-1-infected children in Africa that significant myelin loss in cART-naïve children was
observed in comparison with cART-treated children. However, cART-treated children
also exhibited a significant myelin loss in the corpus callosum [137]. Interestingly,
myelin-related genes encoding myelin-associated oligodendrocyte basic protein, myelin
transcription factor 1 and myelin basic protein are down-regulated in both cART-treated
and untreated HAND patients [138]. Apparently, the impact of antiretroviral drugs on
oligodendrocyte pathophysiology requires further investigation.
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Figure 1. Potential mechanisms for HIV-induced oligodendrocyte/myelin injury.
A, HIV-1 Tat enhances JCV transcription and replication. B, HIV-1 proteins induce
oligodendrocyte apoptosis. C, The progenitor cell proliferation and differentiation are
interrupted in neuroHIV.

Sections 3-7 are from review “Oligodendrocyte Injury and Pathogenesis of HIV-1Associated Neurocognitive Disorders” published on Brain Science. 2016, 6(3), 23.
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8. K+ channels in brain: implications for channelopathy in HAND
K+ channels are highly diverse and expressed on almost all cell types. Normal
function of K+ channels is required for basic cell survival and normal activity. In contrast,
K+ channel hyperactivation, especially outward K+ currents conducted by KV channels,
may cause cell apoptosis in a variety of cell types via apoptotic volume shrinkage.
Enhanced K+ efflux can resultant in apoptotic cell shrinkage, downstream caspase
activation, and further DNA fragmentation [84, 139]. Hyperactivation of K+ channel can
also cause immune cells activation like macrophages, microglia, and T lymphocytes [140,
141]. The non-specific KV blocker 4-AP has been approved by the Food and Drug
Administration to proceed to clinical trial for neurodegenerative disease [142]. Previous
studies from our laboratory describe apoptosis of rat cortical neurons associated with
enhancements of K+ efflux conducted by voltage-gated K+ (KV) channels in HAND. KV1.3
and KV1.5 in microglia are highly involved in pathogenesis of experimental autoimmune
encephalomyelitis animal models and HAND [143-145]. Microglia KV1.3 is involved in
microglial activation-induced neuronal injury [141]. These data suggest KV channels are
closely associated with HIV pathogenesis.
8.1. K+ channels in neurons
Action potential propagation is the most essential character for neural function. The
two most important properties of axonal action potentials are high conduction velocity
with quick recovery. High velocity requires rapid inactivation of Na+ channels and a high
K+ permeability [146]. It is believed that Na+ channels are enriched in the node of
Ranvier, meanwhile, KV channels are enriched at the juxtaparanodes (JXP) (Fig. 2). The
cluster of KV1 family members on neuronal axon JXP indicates myelination [147] [148].
In coculture model of hippocampal neurons and oligodendrocytes, endogenous KV1.2
channels enriched in JXP of myelinated hippocampal axons after two weeks of
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coculturing neurons and oligodendrocytes [149]. In contrast, KV1.2 distribution on
myelinated axons is disrupted within demyelinated lesions in the WM of spinal cord in
experimental autoimmune encephalomyelitis [150]. These data suggest that KV channels,
particularly KV1.2, are essential for axon cable properties.
It has been reported that depolarization-activated K+ currents limit the peak
amplitude of the depolarizing after-potential in both lizard and rat axons [151]. However,
overexcited KV channels hyperpolarize the neuronal membrane increasing the threshold
to trigger action potential, even leading to neuronal death. As mentioned above,
research on programmed cell death has demonstrated the necessary contribution of K+
channels in the process of apoptosis. In previous experiments, our laboratory confirmed
the association of rat cortical neuron apoptosis and increased K+ channel currents in
HIV-1 proteins treated cells [143-145]. While several KV channel subtypes have been
implicated in cortical neuron apoptosis, including KV2.1 [152], KV1.1 [144], KV3.4 [153],
KV4.2, and KV4.4 [154], the specific subtypes involved in HAND pathology and the
mechanism underlying its dysfunction remains to be extensively characterized.
Collectively, these observations suggest that specific KV channel subunits may perform
neurotoxic activity under particular pathological conditions.
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Figure 2. The distribution of voltage-gated ion channels on neural axon. KV1
family members KV1.2 express at the JXP region of axon. Voltage-gated Na+ channels
(NaV) express on the node area.
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8.2. K+ channels in oligodendrocytes
As early in 1988, Betty et al. performed whole cell clamp patch on cultured ovine
oligodendrocytes. They found oligodendrocytes express outward currents considered as
K+ currents, because that represent an transient-inactivating component and noninactivating component, which showed reversal potential at -66 mV and were sensitive to
KV blockers [155]. The transient component decreased within the oligodendrocyte
lineage cell development, while accompanied by an up-regulation of steady-state
outward and inward rectifier current [129, 155, 156]. Generally, KV channel expression
on oligodendrocyte lineage cells correlate with differentiation stage and are more
complex in OPCs than in oligodendrocytes. To date, KV1 subfamily is relatively well
studied in oligodendrocytes [129, 130, 157]. In addition to what has been addressed in
section 7.2., in cultured oligodendrocytes from basal forebrain, high concentration of KCl
(25 mM), which can depolarize cell membrane via inhibiting K+ efflux, approximately
doubles BDNF mRNA expression, while nerve growth factor (NGF) and neurotrophin-3
(NT-3) expression is not altered. The number of cells expressing mature myelin basic
protein positive (MBP+), which is a structural protein of myelin sheath, increased [158].
These data suggest that KV channels activity affect the trophic function of
oligodendrocytes that further affect neuronal function and survival.

Since oligodendrocytes are the most important cell type for myelin sheath production
and maintenance in CNS, K+ channels may act as a mediator in myelin injury and
remyelination by regulating OPC/oligodendrocyte biogenesis. It is not surprising that
apoptosis of oligodendrocytes is an important component of lesion formation. The crucial
role of oligodendrocyte indicates any damage or/and loss of oligodendrocytes may relate
to the observed myelin damage and cognitive deficits in HAND patients.
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8.3. K+ channels in astrocytes
Astrocytes are indispensable for neuronal survival and function, including an
additional beneficial effect on oligodendrocyte regeneration during remyelination.
Astrocytes pivotally regulate extracellular concentration of glutamate and K+ to support
neuron function [159]. During normal neuron firing, K+ ions flow to the extracellular space
from neurons. Increased extracellular K+ concentration can potentially cause membrane
depolarization. Kir4.1 channels in astrocytes may play a critical role in K+ buffering to
avoid neuronal membrane depolarization, which may result in interruption of axonal
conduction and synaptic transmission [160, 161] [162-164]. So far, there is no clear
evidence indicates close association of astrocyte K+ channels and HAND pathogenesis.
Astrocyte Kir channels may serve to provide the network of regulation in K+ and
glutamate concentration in brain [161].
8.4. K+ channels in microglia
Microglia are the residual immune cells in the brain [165]. The protective effect of
microglial immune activation in HAND is mostly temporary. Hyperactivation of microglia
and macrophages are often accompanied with disease progression.

In addition,

depletion of these cells significantly decrease the severity of HIV-1-related CNS
neuropathology [166].
Microglia express several K+ channel families including KV1, KV3, Kir [167-169]. Kir
channels are often considered to be functional on resting microglia. KV1.3 and KV1.5 are
highly involved in pathogenesis of HAND [140, 141, 170]. Activation of microglia leads to
neuronal injury through a mechanism requiring microglial KV1.3 activity. Data published
from our lab found that collected culture medium from KV blocker-treated microglia
attenuate HIV-1 Tat-induced neuronal apoptosis that corresponds with Erk1/2 MAPK
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kinase activation. Moreover, enhancement of outward K+ currents on microglia increases
the cell motility [141]. Blockade of KV1.3 significantly reduce microglia migration to
cellular debris [171]. In addition, Ca2+ activated K+ channels 3.1 (KCa3.1) promote rat
microglia migration [172]. KCa3.1 blocker reduced the microglial activities of
phagocytosis and chemotactic in primary culture [173].

Summary and Discussion
There are increasing interests in myelin sheath loss and WM damage in HIV-1 brain.
The clinical and postmortem manifestations of myelin damage of HAND patients,
contributions

of

BBB

integrity

disruption,

oligodendrocyte

apoptotic

molecular

mechanisms, and OPC regulation imbalance in oligodendrocyte/myelin abnormalities
have been addressed in this chapter. All of these factors potentially involve in generation
of HAND pathology. Given that milder forms of HAND remain prevalent and HIV-1
proteins and toxic factors released from infected cells persist in brain even in the era of
cART, the studies on direct toxicity of HIV-1 viral proteins on oligodendrocytes and
OPCs, as well as neurons, are emerging. Because the transcription of HIV-1 viral protein
continues in the CNS even the viral detection is minimal [174], this concept orchestrates
with the context of changed HAND pathogenesis in cART era, of which inflammation,
encephalitis, and neurodegeneration has been significantly decreased by the advent of
cART. The ways on the regulation of oligodendrocyte lineage cell development are wellestablished including the extracellular pathways, cell to cell contact, and intracellular
pathways. Since NG2+ cell is the biggest population of progenitor cells in human adult
brain, the decreased absolute cell number and proliferation of NPC and OPC may be
less contributive to myelin deficits in HAND. However, the evidences of HIV-1-related
OPC differentiation and remyelination imbalance serve to better understand the impact

25
of remyelination for CNS repair in HAND patients, providing a new therapeutic strategy
[175].
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Chapter 2

Human immunodeficiency virus protein Tat
induces oligodendrocyte injury by enhancing
outward K+ current conducted by KV1.3
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Abstract
Brain white matter damage is frequently detected in patients infected with human
immunodeficiency virus type 1 (HIV-1). White matter is composed of neuronal axons
sheathed by oligodendrocytes, the myelin-forming cells in central nervous system.
Oligodendrocytes are susceptible to HIV-1 viral trans-activator of transcription (Tat) and
injury of oligodendrocytes results in myelin sheath damage. It has been demonstrated
that activation of voltage-gated K+ (KV) channels induces cell apoptosis and
oligodendrocytes predominantly express K+ channel KV1.3. It is our hypothesis that Tat
injures oligodendrocytes via activation of KV1.3. To test this hypothesis, we studied the
involvement of KV1.3 in Tat-induced oligodendrocyte/myelin injury both in vitro and ex
vivo. Application of Tat to primary rat oligodendrocyte cultures enhanced whole-cell
KV1.3 current recorded under voltage clamp configuration and confirmed by specific
KV1.3 antagonists Margatoxin (MgTx) and 5-(4-phenoxybutoxy) psoralen (PAP). The
Tat enhancement of KV1.3 current was associated with Tat-induced oligodendrocyte
apoptosis, which was blocked by MgTx and PAP or by siRNA knockdown of KV1.3 gene.
The Tat-induced oligodendrocyte injury was validated in cultured rat brain slices,
particularly in corpus callosum and striatum, that incubation of the slices with Tat
resulted in myelin damage and reduction of myelin basic protein which were also
blocked by aforementioned KV1.3 antagonists.

Further studies revealed that Tat

interacts with KV1.3 as determined by protein pull-down of recombinant GST-Tat with
KV1.3 expressed in rat brains and HEK293 cells. Such protein-protein interaction may
alter channel protein phosphorylation, resultant channel activity and consequent
oligodendrocyte/myelin injury. Taken together, these results demonstrate an involvement
of KV1.3 in Tat- induced oligodendrocyte/myelin injury, a potential mechanism for the
pathogenesis of HIV-1-associated white matter damage.
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1. Introduction
Neurologic complications of human immunodeficiency virus type 1 (HIV-1) infection
remain common in the era of effective combination antiretroviral therapy (cART). Up to
half of infected individuals develop HIV-1-associated neurocognitive disorders (HAND),
the cause(s) remain obscure. Many studies have revealed a preferential damage to
cerebral white matter in HIV-1-infected brain [8, 41, 82, 91], and such damage is
prevalent even in the era of cART and more severe in patients with HAND [111, 127].
Structure magnetic resonance imaging and diffusion tensor imaging studies in HIV-1infected individuals have revealed a subcortical white matter damage mainly in the
regions of the corpus callosum, internal capsule and other brain regions [41, 54, 91, 92,
111, 176]. Moreover, cognitive impairment in HIV-1-infected individuals with AIDS was
found to be associated with white matter injury in the corpus callosum, internal capsule,
and superior longitudinal fasciculus [41, 176]. It appears that subcortical damage in
white matter plays a more important role than cortical damage in the mediation of HAND
symptoms which are predominantly of the subcortical type [22, 24, 177, 178].
Cerebral white matter consists mostly of myelinated axons and axonal myelination is
formed by oligodendrocytes. The integrity of the myelin sheaths is essential for the
propagation of nerve impulses along axons. It has been demonstrated that myelin pallor,
an abnormality that could reflect a decrease in myelin components [29, 179], is
frequently seen in patients with HIV-1 encephalitis and in cART naïve subjects. Myelin
sheath damage and changes in numbers of oligodendrocytes have also been observed
in HIV-1-infected individuals [90, 180]. In vitro studies have shown that exposure to
recombinant viral envelope protein gp120 resulted in alterations of oligodendrocyte
functional activity and myelin formation in rat oligodendrocytes maintained in a cell
culture system [14, 15], exampling HIV-1 protein impairment of oligodendrocyte/myelin,
which may lead to axonal injury, demyelination and ultimately white matter damage.
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Nevertheless, how HIV-1 proteins induce oligodendrocyte/myelin injury is not fully
understood.
Increasing evidence indicates that activation of voltage-gated K+ channels (KV) is an
essential pathway in programmed cell death [26, 84] and enhancement of outward K+
current results in neural cell apoptosis [181, 182]. Oligodendrocytes express several
subtypes of KV channels including a predominant KV1.3 [129, 183]. A decrease of KV1.3
expression or outward K+ current in oligodendrocytes is essential for synthesis of myelin
structural proteins and suppression of outward K+ current promotes oligodendrocyte
maturation and survival. These results suggest a role of KV1.3 in the regulation of
oligodendrocyte functionality [130, 133]. Moreover, activation of p53 has been detected
in the oligodendrocyte lineage cells in the postmortem brains of HAND patients, but not
in control brains [83], suggesting oligodendrocytes undergo apoptosis in HIV-1-infected
brains. Thus, it is our hypothesis that continued viral replication and viral proteins induce
oligodendrocyte/myelin injury by activation of oligodendrocyte KV1.3 channels, leading to
myelin/white matter damage and HAND pathogenesis. To test this hypothesis, we
studied how HIV-1 protein Tat induces oligodendrocyte/myelin injury, as infected brain
cells continuously express and release Tat protein despite the controlled viral replication
[184, 185]. Our results showed that HIV-1 Tat enhances outward K+ current conducted
by KV1.3 leading to oligodendrocyte/myelin injury.
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2. Materials and Methods
2.1.

Materials. HIV-1 Tat IIIB was purchased from Immunodiagnostic, Inc.

(Woburn, MA). Tat was dissolved in sterile distilled water and, aliquots of Tat were kept
as 50 µg/ml stock solution at -80 °C.
2.2.

Animals. Pregnant Sprague-Dawley rats were purchased from Charles River

(Wilmington, MA) and maintained under the ethical guidelines for the care of laboratory
animals, and all animal procedures were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center.
2.3.

Oligodendrocyte preparation and culture. Oligodendrocyte cell cultures

were prepared as described previously [186] and all culture materials were purchased
from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Briefly, P1-2 neonatal rat
pups were decapitated with large scissors and place the heads in 10 cm-petri dish filled
with cold Hank`s buffered salt solution (HBSS). Microdissecting scissors was used to
carefully cut skin and skull along the midline from neck toward the nose. Brains were
taken out with a spatula and placed to another petri dish contained cold HBSS. The
meninges were removed with forceps under a dissection microscope. Cortex tissue was
dissociated by cutting the brain to two hemispheres and removing hippocampus and
olfactory bulbs.
Dissociated cortex tissue was incubated in 0.25% trypsin and 200 U DNase
contained in HBSS at 37 °C for 15 min. Then 1 ml FBS was added to stop trypsinization.
Homogenate was collected into a 50-ml tube and the contents were triturating by
pipetting several times to separate any tissue block. The tissue suspension was next
collected into a clean 50-ml tube and followed by centrifugation at 1500 r.p.m. for 10 min.
The supernatant was removed and 20 ml HBSS was added to re-suspend the remained
cells/tissues by triturating cells/tissue for about 20 times. The remaining tissue
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suspension was passed through nylon mesh with pore diameter size of 100 µm and 40
µm sequentially. Cells were collected by centrifugation at 1500 r.p.m. for 10 min.
Collected cells were re-suspended in DMEM (with L-glutamine and sodium pyruvate,
Cellgro, Manassas, VA) supplemented with 20% FBS (Gibco, Grand Island, NY) and 1%
penicillin/streptomycin (Gibco). Mixed glia cultures were grown on poly-D-lysine-coated
T75 flasks (Thermo, Nazareth, PA) for 10 d and refreshed medium every 3 d.
To isolate OPCs, the flask was pre-shaken for 1 h on an orbital shaker at a speed of
200 r.p.m. in order to remove microglia. OPCs were isolated by shaking overnight at 200
r.p.m. at 37 °C. Cell suspensions were transferred into non-treated 10 cm petri dishes for
30 min to further separate OPCs by differential adhesion (astrocytes and microglia can
attach to bottom faster than OPCs/oligodendrocytes). OPC-contained supernatant was
collected by slightly swirling petri dish and transferring the supernatant in a sterile 50-ml
tube, then the supernatant was passed through 40 µm nylon cell strainers. OPCs were
collected by centrifugation at 800 r.p.m. for 5 min and suspended in OPC medium
(described below). OPCs were plated onto poly-D-lysine-coated coverslips, culture
dishes, or plates in OPC culture media in a density of 1 × 104/cm2.
Different stages of oligodendrocytes are characterized by unique combinations of
genes [187], and three major markers were chosen to specify the following stages in the
present study: NG2+ OPCs, galactocerebroside (GalC)+ immature oligodendrocytes, and
MBP+ mature oligodendrocytes. Basal chemically defined medium (BDM) was made of
DMEM containing 0.1% BSA, 1% Insulin-Transferrin-Selenium (Gibco), 10 nM D-biotin,
and 10 nM hydrocortisone. NG2+ OPCs were maintained in BDM supplemented with 10
ng/ml PDGF-AA (homodimer PDGF consists of 2 A domains) and 10 ng/ml bFGF (both
from Peprotech, Rocky Hill, NJ) for 0-7 d. GalC+ immature oligodendrocytes were
cultured in the same medium as NG2+ OPCs for additional 3 d. MBP+ mature
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oligodendrocytes were obtained by transferring cells to differentiating medium (BDM, 15
nM triiodothyronine, 10 ng/ml CNTF (Peprotech) and 5 µg/ml N-acetyl-L-cysteine) for 2-3
d (Fig. 3).
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Figure 3. Primary culture of oligodendrocyte lineage cells. Panel A, B, C,
representative fields of OPC culture of 1, 4, and 7 d representatively after isolation from
mixed glial culture. Panel D, a representative field of oligodendrocyte cultured in
differentiating medium for 2 d. A, B, C, D images were taken under white field (×200). E,
Portrayed cell purity revealed by staining with NG2, MBP and GalC respectively
depends on different stages of cells. The nuclei were visualized by Dapi staining. All
Images were visualized by fluorescent microscopy (×400). Cell counting is normalized by
Dapi staining. The table shows corresponding conditions in culture along with the
OPC/oligodendrocyte development.
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2.4. Electrophysiology. Cells were seeded onto 3.5-cm culture dishes for whole-cell
recording of ionic currents. Recording electrodes were pulled from borosilicate glass
micropipettes (WPI Inc., Sarasota, FL) with a P-97 horizontal micropipette puller (Sutter
Instruments, Novato, CA) to a resistance of 5-8 MΩ. The electrode solution contained (in
mM): 140 KCl, 2 CaCl2, 2 MgCl2, 11 EGTA, 10 HEPES/KOH, pH7.3, and had an
osmolarity of 300 mOsm, as measured by a vapor pressure osmometor (WESCOR,
Logan, UT). The standard bath solution contained (in mM): 140 NaCl, 5.4 KCl, 2 CaCl2,
1 MgCl2, 10 HEPES/NaOH, pH7.3. D-sucrose was used to adjust the osmolarity of this
solution to 305 mOsm prior to recording. Stock solutions of KV1.3 specific inhibitors, 5(4-phenoxybutoxy) psoralen (PAP, Sigma) and Margatoxin (MgTx, Sigma), were
prepared in deionized water before being diluted to a working concentration with bath
solution, and applied by super-fusion. External super-fusion of the cells was performed
by exchanging the bath at a rate of 1 ml/min. A Burleigh micromanipulator (PC-5000,
EXFO, Canada) was used to position the recording electrode.
Under 40 × objective lens, cells appeared bright and dimensional were chosen to
patch at. The electrode solution was filled into electrodes by a syringe linked with a
micro-loader tip. Air bubbles were eliminated by tapping pipette several times. Then the
glass electrode was placed onto the pipette holder connected with head stage. A
positive pressure was provided to electrode by giving 0.2 ml air through syringe.
Following this, the electrode was placed into the bath solution and off-set was adjusted
to zero. The oscilloscope showed square current response to the seal test. Under
voltage-clamp mode, the electrode resistant was checked in membrane test function in
Clampex software.
Under the 10 × objective lens, adjusted the focus onto the tip of electrode and then
switched the objective lens to 40 ×. The electrode was slowly approached to the chosen
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cell by the micromanipulator. During approaching, it was important to keep the focus on
the tip of electrode but not the cells. When the cells were becoming clearer, the
electrode tip was being closer to the cell. The electrode tip was positioned to touch the
cell surface at the middle right where close to the center of cell body. Once get touched,
the positive pressure was released and instead, a negative pressure was applied to gain
a GΩ seal. The oscilloscope showed flat while GΩ seal was achieved. Followed seal, the
fast capacitance was corrected.
To rapture the cell membrane, further suction was applied by the syringe. Once the
membrane was broken through, the current response showed exponential decay. The
membrane capacitance of each cell was read and recorded under cell mode in
membrane test function. The membrane capacitance was adjusted by at least 70%. The
currents were recorded in Clampex.
Whole-cell K+ currents were induced by applying voltage steps from -150 mV to +60
mV in increments of 15 mV, and current amplitudes were measured at the peak for each
test potential. Current density (pA/pF) was calculated by dividing the digitized current
values by whole-cell capacitance, which represents cell membrane surface area. All
experiments were done at room temperature (22-23 °C). Recordings were obtained with
an Axopatch-200B amplifier (Molecular Devices, Sunnyvale, CA). Current signals were
filtered at 1 kHz and digitized at 5 kHz using a Digidata 1440A interface (Molecular
Devices). The current and voltage traces were displayed and recorded on a computer
using Clampex 9.0 data acquisition and analysis software (Molecular Devices). Data
were analyzed by Clampfit 10.0 (Molecular Devices). All final graphics in the present
work were constructed by Origin 8.0 (OriginLab, Northampton, MA).
2.5.

MTT Assay. MTT assay was used to assess cell viability. Cells were cultured

in 48-well plates for MTT assay to minimize diversity between replicates. The 3-(4,5-
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Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) was prepared in sterile
PBS at concentration of 5 mg/ml (10 ×) and stored at -20 °C. The working solution was
made by diluting the stock MTT solution 10 times with DMEM. The pre-treated cells
were exposed to working solution and incubated in 37 °C for 2 h. The MTT solution was
discarded and replaced with 150 µl dimethyl sphingosine (DMSO). Cells were then
shaken for 15 min at 200 r.p.m. for completed lysis. The dissolved solution was
transferred of 100 µl from each well to a 96-well plate and, 96-well plate was eventually
placed to a plate reader and tested the optical density at 560 nm.
2.6. Apoptosis Assay.
A) Terminal deoxynucleotidyl transferase dUTP nick end labeling (Tunel) staining
was performed with the in situ cell death detection kit (Fluorescein, Roche Applied
Science, Indianapolis, IN). Cultures plated on coverslips were fixed in 4%
paraformaldehyde for 1 h at room temperature and permeabilized with 0.1% Triton X100 for 30 min. Cover slips were washed 5 min × 3 times with PBS. Tunel reaction
mixture

was

made

by

adding

label

solution

to

enzyme

solution

(terminal

deoxynucleotidyl transferase and fluorescein-labeled nucleotides) at a ratio of 1:50.
Each cover slip was prepared 30 µl of reaction mixture. The reaction mixture was
applied onto clean Para film and, cover slips were flipped onto reaction mixture solution
drops and incubated for 90 min at 37 °C. After washing, coverslips were mounted in
vectashield mounting medium with Dapi stain (Vector Laboratories, Burlingame, CA) and
cells were visualized by a fluorescent microscope. Apoptosis was assessed in each of
three experimental preparations by examining 10 microscopic fields per experimental
group.
B) Propidium iodide (PI) staining. Fixation of cultures was performed same as
mentioned above in Tunel staining. Cells were briefly equilibrated in 2 × SSC (0.3 M
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NaCl, 0.03 M sodium citrate, pH 7.0), and then incubated the in 100 μg/ml DNase-free
RNase in 2 × SSC for 20 minutes at 37°C to remove RNase. Coverslips were rinsed 1
minute × 3 times with 2 × SSC. PI solution was made at a concentration of 500 nM by
diluting the 1 mg/ml (1.5 mM) stock solution 1:5000 in 2 × SSC. Cells were incubated
with the diluted working staining solution for 1 m. Cells were washed 4 times with
shaking in 2 × SSC. Excessed buffer was drained from the coverslips and, coverslips
were mounted in vectashield mounting medium with Dapi stain. The analysis procedures
were performed same as Tunel assay.
2.7.

Brain slices culture. Coronal brain slices were prepared from 21-d-old

neonatal Sprague-Dawley rats. The culture procedures were performed as described by
Stoppini, etc [188]. All surgical instruments were autoclaved. Vibrotome (Campden
instruments, MA752 Motorised advance vibroslice) was sterilized by exposure to
ultraviolet light for 1 h. The 2% of agarose gel was prepared in sterilized water to help
positioning rat brains. Artificial cerebrospinal fluid (ACSF) contained (in mM) NaCl 124.0,
KCl 3.0, CaCl2 2.0, MgCl2 2.0, NaH2PO4 1.25, NaHCO3 26.0, and glucose 10.0, pH 7.2.
The culture medium consisted of 50% MEM with HEPES (Gibco), 25% horse serum
(Atlanta biological, Flowery Branch, GA), 25% Hank`s solution (Invitrogen), and 6.5
mg/ml glucose. Inserts with 30 mm diameter, sterile, porous (0.8 µm), transparent and
low-protein-binding membrane were placed into 6-well plates as scaffold for the brain
slices.
Agarose gel was cut to a small cube and fixed onto stage of vibrotome by super glue
(Fig. 4 Top). Rats were anesthetized with isoflurane, and then quickly decapitated by
small animal decapitator (Stoelting, 51330). The whole brain was dissected and fixed
onto the stage of vibrotome next to agarose gel cube (Fig. 4 Top). The stage was placed
into cutting chamber filled with pre-cooled and oxygenated ACSF. Oxygen was provided
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to ACSF during the whole cutting procedure. Slices of 400 µm were cut and separated in
ACSF. The slices were then transferred on to culture insert plated in 6-well plate with 1
ml/well pre-warmed (37 °C) culture medium. The 6-well plates were then kept in
incubator at 37 °C with 5% CO2. It was important to keep the slices placed on the
interface between air and medium (Fig. 4 Bottom).
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Figure 4. Illustration of the cutting and culturing technique. Top: photograph of
cutting brain slices. Bottom: photograph of a culture plate containing brain slices.
Medium should not cover the insert membrane.
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2.8.

Cryostat section. The brain slices were washed with PBS for 3 times after

treatments, then fixed with 4% paraformaldehyde for 24 h. The tissue was then
progressively changed into graded 10%, 20%, and 30% sucrose/PBS solution each for
24 h for cryoprotection. The tissues were orientated and embedded within OCT and
quickly frozen in -80 °C. The tissue blocks were cut into 10 µm sections by Leica
cryostat (LEICA CM1850 UV).
2.9.

Immunofluorescences. The prepared brain sections were blocked and

permeabilized in 10% goat serum/0.1 % Triton/PBS solution for 30 min in room
temperature. The slides were dried carefully, and the tissue sections were circled by
hydrophobic pen, followed by applying 50 µl of the primary anti-rat MBP antibody (1:200,
Chemicon) for each section. Slides were placed in a humidified chamber and incubated
at 4 °C overnight. Next day, after washing the sections with PBS 5 min × 3 times,
sections were incubated in goat anti-rat fluorescent secondary antibody (1:1000,
Invitrogen) for 2 h in room temperature by using the same technique as described for
primary antibody incubation. Sections were washed 5 min × 3 times and mounted with
coverslips in vectashield mounting medium with Dapi (Vector Laboratories, Inc.
Burlingame). The myelin sheath was visualized under fluorescent microscope.
2.10.

Total protein extraction. The whole cell lysates were prepared in RIPA

buffer (BioRad, Hercules, CA) while tissue was lysed in tissue extraction reagent
(Invitrogen). In details, following experimental treatments, cells or brain tissue were
washed twice with ice-cold PBS and then PBS was aspirated. For cultured cells, 150 µl
RIPA buffer supplemented with protease inhibitor was added to each well of 6-well plate.
Cells were detached by scraping the well bottom and gently transferred into a
microcentrifuge tube. For brain tissue, dissected corpus callosum and striatum from
cultured brain slices were put into separate tubes, followed by addition of 200 µl tissue
homogenate reagent to each tube. Sonication was performed 3 times for 15 seconds to
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lyse brain tissues. Homogenate was then projected to a freeze-thaw cycle for complete
lysis. Cell lysate or tissue homogenate were centrifuged at 10,000 r.p.m. for 10 min and
supernatant was collected to a fresh tube. Next, 20 µl of each sample was taken out for
protein concentration determination. A quarter of the sample volume of 5 × loading
buffer was added to protein samples. Protein samples were denatured by boiling water
for 7 min, and stored in -20 °C for western blotting.
5 × loading buffer consisted of 0.25% Bromophenol blue, 0.5 M dithiothreitol, 50%
glycerol, 10% sodium dodecyl sulfate, and 0.25 M Tris-Cl (pH 6.8).
2.11.

Extraction of total membrane proteins. Membrane protein enriched

fraction was extracted by Membrane Protein Extraction Kit (BioVision Inc, CA). Cells
were cultured in 6-cm culture dishes for membrane protein extraction. After experimental
treatments, cells were washed twice with ice-cold PBS. Firstly, 1 ml homogenization
buffer was applied to each culture dish. Cells were scraped and then homogenized by
vortex for about 10 times. Homogenate was then collected to a 1.5-ml tube and,
centrifuged at 700 g for 10 min at 4 °C. The supernatant was transferred to a fresh tube
and the pallet was discarded. Collected supernatant was centrifuged from at 10,000 g for
30 min at 4 °C.
Following the centrifugation, protein would be separated to the cytosol protein
fraction (supernatant) and the total cellular membrane protein fraction (pallet). Dissolve
the pellet in 60 µl 0.5% Triton X-100 in PBS buffer. Then 20 µl from each sample was
taken for concentration determination.
2.12.

Protein concentration determination.

The BCA protein assay kit

(ThermoFisher Scientific, Waltham, MA) was employed to quantify protein concentration.
BCA working reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part of
BCA reagent B. The needed total volume of working reagent was determined by the
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following equation: (number of standards + number of unknowns) × (number of
replicates) × 100 µl = total volume of working reagent required.
Standards were prepared by diluting 2 mg/ml albumin ampules in working reagent to
200, 100, 50, 25, 12.5 µg/ml. Then 100 µl of each standard was put into a 96-well plate.
At separate wells, 100 µl of working reagent only was placed as zero. Next, 10 µl of
each unknown samples was diluted to 90 µl working reagent. Every standard and
sample was duplicated. After all samples were prepared, the plate was incubated in
37 °C for 30 min. The plate was then placed in a plate reader and the absorbance of all
the samples were measured with the testing wavelength at 560 nm.
Standard curve was made by plotting the average blank-corrected measurement for
each albumin standard versus its concentration in µg/ml. The standard curve was used
to determine the protein concentration of each unknown sample. The volume for 15 µg
protein of each sample was calculated and then the denatured samples were projected
to Western blotting.
2.13.

Western blotting. 10 × Tris/glycine buffer, 10 × Tris/glycine/SDS buffer, 10%

SDS, and 30% Acrylamide/bis solution were all purchased from Bio-Rad. The 10 × TBS
(Tris-buffered saline, 1 liter) was prepared by dissolving 24.2 g Tris base, 80 g NaCl in
distilled water, and adjust pH to 7.6 with HCl. Washing buffer was prepared by diluting 1
ml 100% Tween-20 to 1 liter 1× TBS (TBST). Separating gel (10% )consisted of 1.5 mM
Tris-HCl (pH 8.8) 2.5 ml, ddH2O 4.0 ml, 30% acrylamide/bis solution 3.3 ml, 10% SDS
100 μl, 10% ammonium persulfate 100 μl, and TEMED 5 μl. Stacking gel (5%) consisted
of 1mM Tris-HCl (pH 6.8) 0.63 ml, ddH2O 3.4 ml, 30% acrylamide/bis solution 0.83ml，
10% SDS 100 μl，10% ammonium persulfate 100 μl，TEMED 5 μl.
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Proteins were firstly separated by electrophoresis depending on the molecular weight.
In details, 15 µg protein of each sample was loaded onto SDS-polyacrylamide gels.
Electrophoresis was run under 70 mV constant voltage and switched to 110 mV when
samples enter lower separating gel. Electrophoresis was stopped when the
Bromophenol blue reached the bottom edge of SDS-polyacrylamide gel.
After electrophoresis, proteins were transferred from gel to a polyvinylidene difuoride
(PVDF) membrane by 100 mV constant voltage in 1 × Tris/glycine/SDS buffer containing
20% methanol for 70 min at 4 °C. The PVDF membrane was then blocked in 5% dry milk
(3% BSA for phosphorylated-protein examination) in TBS for 1 h in room temperature.
Following blocking, membranes were incubated in primary antibodies diluted in blocking
buffer at 4 °C overnight. Primary antibodies were rabbit polyclonal anti-KV1.3 (1:100,
Alomone Lab, Israel), rat monoclonal anti-MBP (1:500, MAB386, Chemicon/Millipore,
Billerica, MA) and mouse monoclonal anti-β-actin (1:5000, Sigma). Afterwards,
membranes were washed in TBST 10 min × 3 times and then incubated in HRPconjugated anti-rabbit, anti-rat or anti-mouse secondary antibodies (1:10,000, all from
Jackson ImmunoResearch Laboratories, West Grove, PA) for 1.5 h at room temperature.
Finally, membranes were washed in TBST 10 min × 3 times and incubated with Pierce
ECL Western blotting substrate (Thermo Scientific, Rockford, IL), imaged by the
FluorChem M system (ProteinSimple, Santa Clara, CA), and band densities were
measured by Alphaview software (ProteinSimple).
2.14.

siRNA silencing. Pre-designed ON-target plus SMARTpool siRNA against

rat KCNA3 (KV1.3, NM-019270) mRNA was purchased from Dharmacon, Inc. (Chicago,
IL). Non-targeting (NT) siRNA (rat) (Dharmacon, Inc) was transfected at the same
concentration as control. KV1.3-siRNA and NT-siRNA were transfected 72 h in prior to
gaining the protein level knockdown.
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OPCs were plated into 6-well plates at a density of 0.35 × 106 cells/well. Stock siRNA
was diluted to 5 μM siRNA solution in RNase-free siRNA buffer solution from stock
solution in a sterile tube. For each well, 10 μl of the prepared siRNA was diluted to 190
μl DMEM, labeled as Tube A. In separate tubes, 2 μl DharmaFECT transfection reagent
was diluted with 198 μl DMEM labeled as Tube B. Each tube was shaken to mix solution
and incubated at room temperature for 5 min. The content was gently mixed from Tube
A to Tube B by pipetting carefully up and down several times. Mixed solution was
incubated for 20 minutes at room temperature. Then 1.8 ml of BDM was added to the
mixed contents for a final volume of 2 ml transfection medium and a final siRNA
concentration of 25 nM. The culture medium was refreshed with transfection medium
and incubated cells at 37 °C in 5% CO2 for 72 h.
2.15.

HEK293 cell line culture. HEK293 cells were kindly provided by Dr. Buch.

The frozen cells-contained vial was thaw in 37 °C water bath by gentle agitation. The vial
was removed from the water bath as soon as the contents were thawed. The contents
were transferred in to a fresh 10-ml tube containing 9 ml culture medium (DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin). Cells were pelleted by
centrifugation at 800 r.p.m. for 5 min. The supernatant was discarded and cells were resuspended in 20 ml culture medium and seeded in T75 culture flask. Cells were kept in
37 °C, 5% CO2 atmosphere and replaced with 10 ml fresh medium every the other day
until the cells were ready for experiments or to be subcultured. For subculture, the
culture medium was removed and cells were washed with sterile PBS twice, 3 ml of 0.25%
Trypsin-EDTA solution was added to culture flask for 5 min to detach the HEK293 cells.
After achieving complete detachment, 6 ml of culture medium was added to stop
trypsinization. Cells were collected by centrifugation at 800 r.p.m. for 5 min and then resuspended in 15 ml culture medium. Aspirations were performed for about 50 times to

47
dissociate cells. Aliquots of the cell suspension were placed into new flasks or culture
plates at a density of 6 × 103/cm2 for continue culture or 6 × 104/cm2 for overexpression.
2.16.

KV1.3 overexpression. The pJK and pJK/KV1.3 plasmids are kind gifts from

Dr. Erich Gulbins [189]. The HEK293 cells were seeded in 6-well plates at a density of
0.6 × 106/well and, grow overnight to reach 70-90% confluent. Lipofectamine 2000
reagent was diluted in Opi-MEM (Invitrogen) at a ratio 5 µl: 95 µl. The pJK or pJK/KV1.3
plasmid at amount of 2.5 µg was diluted in Opi-MEM to make the final volume at 100 µl.
Diluted plasmids were added to each tube of diluted lipofectamine 2000 and, incubated
at room temperature for 15 min. DNA-lipofectamine complex were applied to cells.
Transfected-cells were collected and lysed after 48 h.
2.17.

Pull-down assay. The HEK293 whole cell lysate was prepared same as

described above in section 2.10.. Rat brain tissue sample was homogenized in the
isotonic sucrose homogenization buffer (2 ml) containing 0.32 M sucrose, 10 mM
HEPES, pH 7.4, 2 mM EDTA, and a protease inhibitor cocktail (Thermo Scientific,
Rochester, NY) in a glass grinding vessel with a motor driven Teflon pestle at 700 r.p.m..
The homogenate was then centrifuged at 800 g for 10 min at 4 °C. The supernatant was
aspirated into a new tube and centrifuged at 12,000 g for 15 min at 4 °C. Pellets were
dissolved in buffer containing 10 mM HEPEs, 1% Triton X-100 (pH 7.4) and proteinase
inhibitor cocktail for 60 min at 4 °C with rotation. Then the tube was centrifuged at
12,000 g for 15 min at 4 °C. The supernatant (membrane enriched part) was collected
for pull down assay. GST-HIV-Tat recombinant protein (1 µg for transfected-HEK293
and 10 µg for rat brain tissue protein) were put into protein lysate with rotation overnight
at 4 °C. The next day, 50 µl sepharose beads (GE health) were put into the rotating
tube for another 3 h rotation. The beads were collected by centrifugation of 5,000 g for 2
min and followed with three times wash by PBS. Then the beads were added with 30 µl
2 × loading buffer boiled 95 °C for 10 min to elute the binding protein complex. The
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eluted samples were subjected to Western Blot for analysis of KV1.3 presence with
specific KV1.3 antibody (1:1000, NeuroMab).
2.18.

Co-immunoprecipatation (Co-IP). For native protein Co-IP, rat brain was

taken from 30-d-old Sprague Dawley rat and homogenized in the tissue extraction buffer
(Invitrogen) with addition of proteinase inhibitor cocktail (Sigma). Sonication was
performed 3 times for 15 seconds to lyse tissues. Homogenate was then projected to a
freeze-thaw cycle for complete lysis. Then homogenate was centrifuged at 10,000 r.p.m.
for 10 min and supernatant was collected to a fresh tube.

BCA assay was then

performed as described to quantify protein. The amount of 1 mg protein was taken for
co-IP. To pre-clear protein lysate, 20 µl of 50% Protein A magnetic beads (GE
Healthcare, Sweden) were added to lysate and then incubated with rotation at 4 °C for 1
h. Beads were pelleted by centrifugation at 1000 g for 30 s. The supernatant was
collected to a fresh tube for immunoprecipitation. KV1.3 mouse primary antibody
(Neuromab, 10 µl) was added to pre-cleared lysate and incubated with rotation overnight
at 4 °C. Next day, 20 µl of Protein A magnetic beads was added and incubated with
rotation for 30 min at 4 °C. Bead was pelleted by centrifugation at 1000 g for 30 s. The
supernatant was discarded and pellet was washed with 500 µl tissue extraction buffer for
5 times. Pellet was re-suspended in 1 × protein loading buffer and proceeded to Western
Blotting for analysis of p-Src (Cellsignaling, 1:1000) presence.
2.19.

Statistics. All data are expressed as mean ± S.D. unless otherwise indicated.

Statistical analyses were performed by student`s t test or one-way ANOVA followed by a
Fisher`s least-significant difference test for multiple comparisons. The difference
between groups was considered significant at p < .05.
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3. Results
3.1.

HIV-1 protein Tat enhancement of KV1.3 current in oligodendrocyte

lineage cells
To determine if HIV-1 protein Tat induces oligodendrocyte/myelin injury via activation
of KV1.3 channels, we first examined the expression of KV1.3 current in oligodendrocyte
cells. Two specific KV1.3 channel antagonists, MgTx and PAP, were utilized to isolate
KV1.3-conducted K+ currents. Whole-cell outward K+ currents, induced by voltage-steps,
were recorded in oligodendrocytes at the age of 14 DIV in the absence (total) and
presence of specific KV1.3 antagonist 5 nM MgTx (IC50 ~1 nM) or 10 nM PAP (IC50 = 2
nM [190]) in the perfusate. KV1.3 currents were calculated by subtraction of the outward
K+ currents recorded 20 minutes after the entrance of MgTx (MgTx) or PAP (PAP) into
the bath chamber from the outward K+ currents recorded in the absence of MgTx or PAP
in the perfusate (Total). These MgTx-sensitive and PAP-sensitive currents are KV1.3
currents as illustrated at the right column (Fig. 5). These results clearly demonstrated the
expression of KV1.3 currents in oligodendrocyte lineage cells.
After demonstration of KV1.3 expression in the oligodendrocytes, we next tested
effects of Tat on KV1.3 current recorded in the oligodendrocytes. Experiments were
carried out on two groups of oligodendrocytes, one was untreated controls (Ctrl, n = 6)
and the other was incubated with Tat (Tat, 50 ng/ml, n = 6) for 2 h before conducting
electrophysiology recording. Whole-cell outward K+ currents were recorded in the
absence (Total) and presence of MgTx (MgTx). The KV1.3 (KV1.3) currents were
calculated as described above. Incubation of the oligodendrocytes with Tat produced an
increase of KV1.3 currents (Fig. 6A). The average peak current densities, when
measured at +60 mV, were 61.17 ± 5.66 pA/pF in control oligodendrocytes and 94.60 ±
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3.59 pA/pF in Tat-treated cells (Fig. 6B).

The difference is statistically significant,

indicating Tat enhancement of KV1.3 current in oligodendrocytes.
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Figure 5. Expression of KV1.3 current in oligodendrocytes. Representative traces
are whole-cell outward K+ currents recorded in oligodendrocytes before (total) and after
super-fusion of oligodendrocytes with PAP (10 nM) or MgTx (5 nM). KV1.3-excluded
currents showed in the middle column were recorded 20 min after super-fusion of
oligodendrocytes with each specific KV1.3 antagonist as indicated. The KV1.3 antagonistsensitive currents, which represent the KV1.3 current, are calculated by subtraction of
individual KV1.3-excluded current from corresponding total current and shown in the right
column. KV1.3 current contributes to approximately 50% of the total outward K+ currents
in oligodendrocytes.
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B

A

Figure 6. Tat increased KV1.3 current on oligodendrocytes. Data were obtained from
oligodendrocytes with (Tat) or without (Ctrl) incubation of 50 ng/ml Tat for 2 h. Panel A
shows representative whole cell outward K+ currents recorded before (total, left column)
and 15 min after addition of 5 nM MgTx (MgTx, middle column) to the bath. The KV1.3
currents were then isolated by subtraction of outward K+ currents recorded in the
presence of MgTx from the total currents (KV1.3, right column). Panel B is a summary
bar

graph

illustrating

average

KV1.3

current

density

(pA/pF)

obtained

from

oligodendrocytes without (Ctrl) and with Tat treatment (Tat). Note that Tat significantly
increased KV1.3 current density measured at +60 mV. ** p < .01 vs. control Ctrl. n = 6 in
each group.
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3.2. Involvement of KV1.3 in Tat-induced oligodendrocyte injury
It has been reported that enhancement of outward K+ current causes neural cell
apoptosis [181, 182]. To explore whether the Tat enhancement of KV1.3 current is
associated with Tat-mediated neurotoxic activity, we examined involvement of KV1.3
channel in Tat-induced oligodendrocyte injury by MTT assay in the absence and
presence of pre-added (1 h earlier) PAP (10 nM), a specific KV1.3 antagonist. Our
results showed that addition of Tat to the culture media for 48 h significantly decreased
oligodendrocyte viability in a concentration-dependent manner. At the concentrations of
50 ng/ml and 100 ng/ml, Tat reduced oligodendrocyte viability to 80.50% ± 6.81% of
control level (p < .05) and 64.76% ± 5.83% of control level (p < .01), respectively,
indicating that Tat induces oligodendrocyte injury in vitro (Fig. 7).

Increase of Tat

concentrations to 200 ng/ml and 400 ng/ml did not produce further decrease of
oligodendrocyte viability (Fig. 7). The Tat-induced decrease of oligodendrocyte cell
viability was blocked by pre-treatment of the oligodendrocytes with PAP, demonstrating
an involvement of KV1.3 in Tat-induced oligodendrocyte injury (Fig. 7). It has been
shown that Tat concentration can reach as high as ∼40 ng/ml in the serum of HIV-1positive patients, with potential higher concentrations at local tissue sites because Tat in
vivo might be sequestered by endogenous anti-Tat and/or by glycosaminoglycans [32,
191]. Thus, Tat at a concentration of 50 ng/ml was considered as being physiological
relevant and adopted for the subsequent studies reported hereinafter.
Increasing evidence indicates that activation of KV channels is an essential pathway
in programmed cell death [26, 84] and activation of apoptotic pathway has been
observed in both HAND patients and Tat transgenic mice [12, 83]. Whether Tat
enhancement of KV1.3 current contributes to Tat-induced oligodendrocyte apoptosis was
further investigated using pharmacological and molecular genetic approaches. As
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anticipated, addition of Tat to the oligodendrocyte culture for 48 h resulted in
oligodendrocyte apoptosis as detected by Tunel assay. Heated Tat (boiled for 15
minutes) had no significant effect on inducing oligodendrocyte apoptosis (Fig. 8). The
Tat-induced apoptosis was significantly attenuated by pre-addition (1 h earlier) of
specific KV1.3 antagonists PAP (10 nM) or MgTx (5 nM) to the culture media. In contrast,
pre-addition of Guangxi Toxin (GxTx), a specific antagonist for K+ channel KV 2.1 which
is also expressed in oligodendrocytes [162], failed to block Tat-induced oligodendrocyte
apoptosis. Addition of PAP, MgTx or GxTx each alone had no apparent effects on
oligodendrocyte apoptosis. These results showed a clear involvement of KV1.3 in Tatinduced oligodendrocyte apoptosis (Fig. 8). The Tat-induced oligodendrocyte apoptosis
was also blocked through genetic knockdown of KV1.3 gene. As shown in Fig. 9,
transfection of oligodendrocytes with KV1.3-siRNA for 72 h prevented Tat-induced
oligodendrocyte apoptosis. In contrast, oligodendrocytes transfected with Non-targeting
(NT) siRNA (controls) did not block Tat-induced oligodendrocyte apoptosis.
siRNA per se had no effect on oligodendrocyte cell apoptosis.

KV1.3-

In parallel with the

experimental data obtained with pharmacological approaches, these results further
demonstrated an involvement of KV1.3 in Tat-induced oligodendrocyte injury.
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Figure 7. Blockade of KV1.3 attenuated Tat-induced oligodendrocytes injury.
Oligodendrocyte cultures were exposed to Tat for 48 h at different concentrations as
indicated with or without pre-addition of 10 nM PAP for 1 h. Tat produced a significant
reduction of oligodendrocyte cell viability at concentrations  50 ng/ml. Tat-mediated
reduction of oligodendrocyte cell viability was prevented by addition of a specific KV1.3
antagonist PAP, suggesting the Tat-mediated reduction of oligodendrocyte cell viability
was mediated via KV1.3. Data presented were from 6 independent experiments. *p < .05
and **p < .01 vs. control;

##

p < .01 as indicated.
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Figure 8. Involvement of KV1.3 in Tat-induced oligodendrocyte apoptosis.
Oligodendrocytes were exposed to Tat (50 ng/ml) for 48 h with or without pre-addition (1
h earlier) of PAP (10 mM), MgTx (5 nM), Panel A exhibits Tunel staining (green in color)
revealed that Tat induced oligodendrocyte apoptosis (Tat) and the Tat-induced
oligodendrocyte apoptosis was attenuated by pre-addition of PAP (PAT + Tat), MgTx
(MgTx + Tat) or GxTx (GxTx + Tat) to the cultures. Intact cell nuclei were visualized with
Dapi (blue in color). In a subset of cultures, PAP (PAP), MgTx (MgTx), GxTx (GxTx) and
heat-inactivated Tat (50 ng/ml, heated-Tat) were tested individually. Panel B shows
average percentage of apoptotic cells from five independent experiments. There were
nine different experimental treatments in each experiments and 10 randomly selected
visual fields were counted for each experimental treatment. As showed in Panel b, Tatinduced oligodendrocyte apoptosis was attenuated by either specific KV1.3 antagonist
PAP or MgTx, but not by GxTx, a specific antagonist for KV2.1, demonstrating an
involvement of KV1.3 in Tat-induced oligodendrocyte apoptosis. ** p < .01 vs. control; #p
< .05 vs. Tat;

##

p < .01 vs. Tat. Scale bar equals 20 µm.
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Figure 9. Knockdown of KV1.3 gene prevented Tat-induced oligodendrocyte
apoptosis. Cultured oligodendrocytes were transfected with KV1.3-siRNA for 72 h to
knockdown KV1.3 gene or with non-targeting siRNA as a control.

Following siRNA

transfection, 50 ng/ml Tat or heat-inactivated Tat was applied to the transfected cells for
another 48 h. Representative PI staining images (Panel A) showed that knockdown of
KV1.3 gene prevented Tat-induced oligodendrocyte apoptosis (siRNA-KV1.3+Tat). In
contrast, non-targeting siRNA (NT) failed to block Tat-induced oligodendrocyte apoptosis
(NT + Tat). Non-targeting siRNA (NT) and KV1.3-siRNA (siRNA-KV1.3) per se had no
apparent effect on basal levels of apoptosis. Also, oligodendrocytes transfected with NT
and treated with Heat-inactivated Tat (NT + Heated-Tat) had no apparent effect (image
not shown). This study was conducted in three independent experiments. Apoptotic
cells were counted from 10 randomly selected visual fields in each experiment with
different experimental treatments, and then calculated and shown in Panel B that
knockdown of KV1.3 gene prevented Tat-induced oligodendrocyte apoptosis. ** p < .01
vs. NT;

##

p < .01 vs. NT + Tat. Scale bar equals 20 µm.
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3.3.

KV1.3 blockade prevented oligodendrocyte from Tat-induced MBP

reduction and myelin loss.
MBP is an essential myelin structural protein and decreased levels of MBP
expression in oligodendrocytes reflect an impaired ability of oligodendrocytes on axonal
myelination. Classically, MBP has three isoforms that arise from different transcription
start sites and the protein band at 18.5-kDa is considered as the predominant isoform
essential for CNS myelin stability [192, 193].

To determine Tat influence on MBP

expression, we specifically examined the protein band at 18.5-kDa by Western blot
analyses.

The same treatments as described in assessing oligodendrocyte cell

apoptosis (Fig. 8 and 9) were employed in the experiments. The effectiveness of siRNAKV1.3 on knockdown KV1.3 gene was first evaluated.

As shown in Fig. 10A,

oligodendrocytes transfected with siRNA-KV1.3 revealed the KV1.3 gene silence as
evidenced by a significant reduction on the levels of KV1.3 protein expression when
compared with the KV1.3 protein expression levels in non-targeting siRNA (NT)-treated
oligodendrocytes. The involvement of KV1.3 on Tat-induced alteration on MBP
expression was then determined through molecular genetic and pharmacological
approaches. As illustrated in Fig. 10C, treatment of oligodendrocytes with Tat
significantly decreased the levels of MBP expression compared to the MBP levels
detected in non-treated controls (p < .01). The Tat-induced decrease of MBP expression
was blocked by specific KV1.3 channel antagonists PAP and MgTx, but not by a KV2.1
antagonist GxTx, demonstrating activation of KV1.3 underlies Tat-mediated decrease of
oligodendrocyte MBP expression. Such experimental results were duplicated by using
siRNA to knockdown of KV1.3 gene (Fig. 10B). These results showed Tat decreases
oligodendrocyte myelination ability via KV1.3.
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Since there were no neurons in oligodendrocyte cell cultures in above experiments, it
was difficult to evaluate if Tat decrease of MBP expression reflects HIV-1-associated
oligodendrocyte/myelin damage seen in HIV-1-infected individuals. Alternatively,
cultured brain slices were utilized as an ex vivo oligodendrocyte/myelin injury model to
address possible pathophysiological processes in an in vivo condition. Coronal brain
slice cultures, prepared from young adult rats, were utilized to examine Tat alteration of
myelination. Tat was added to slice culture for 72 h and specific KV1.3 antagonists were
added 1 h prior to addition of Tat. The treated and untreated slices were then subject to
MBP immunostaining to examine myelin integrity and myelination was evaluated by
western blot analyses of MBP expression. The brain regions of corpus callosum and
striatum were selected for analyses of myelin sheath integrity. The MBP reactivity in the
corpus callosum was continuously aligned and exhibited an intact appearance in control
(Ctrl) brain slices, whereas the MBP reactivity in the corpus callosum was discontinuous
aligned and disorganized in brain slices treated with Tat (Fig. 11A left). In comparison
with the clear and intense axonal bundles seen in the striatum of control brain slices, the
striatum of Tat-treated brain slices showed impaired axonal bundles (Fig. 11A right).
These abnormalities of myelinated nerve fibers and bundles were not observed in the
slices treated with Tat combined with KV1.3 antagonists PAP and MgTx, illustrating the
blockade of Tat-induced impairments of myelin sheaths in both brain regions by KV1.3
antagonists. In parallel with the morphological changes observed in the corpus callosum
and striatum, Tat decreased the levels of MBP protein expression in these two brain
regions and the Tat-associated decrease of MBP protein expression was also blocked
by specific KV1.3 antagonists (Fig. 11B), further support the notion that Tat induces
oligodendrocyte/myelin/white matter injury via KV1.3.
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Figure 10. Involvement of KV1.3 in Tat-induced oligodendrocyte MBP reduction.
Cells were treated the same as described in Fig. 8 and 9. Data presented were from
three independent experiments. Panel A shows a representative gel demonstrating a
successful KV1.3 protein knockdown as a consequence of KV1.3 gene silencing. Panel B
exhibits representative western blot results showing Tat-induced reduction on MBP
expression was blocked by knockdown of KV1.3 gene (upper). The band densitometric
bar graph (lower) revealed a significant Tat reduction of MBP expression and the Tatassociated reduction of MBP expression was abolished by genetic KV1.3 silence. Panel
c illustrates Tat reduction of MBP expression was pharmacologically attenuated by
specific KV1.3 antagonists, PAP and MgTx, but not by GxTx, a specific KV2.1 antagonist,
demonstrating that Tat decrease of oligodendrocyte MBP expression via KV1.3.
*p < .05 vs. ctrl or non-targeting siRNA (NT); ** p < .01 vs. control or NT; #p < .05 vs. Tat
or NT + Tat; ## p < .01 vs. Tat or NT + Tat.
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Figure 11. Tat-induced myelin injury in brain slices and its blockage by KV1.3
antagonists. Cultured brain slices were exposed to 50 ng/ml Tat for 72 h with or without
pre-addition (1 h earlier) of 10 nM PAP or 5 nM MgTx. Panel A, representative images of
MBP immunofluorescence staining in corpus callosum (CC) and striatum (ST). Intact cell
nuclei were visualized with Dapi. Tat impaired the myelin and nerve bundle integrity in
the CC and ST. Panel B, western blot analyses of MBP expression in brain tissues of
the CC and the ST dissected out from cultured brain slices and lysed in tissue extraction
buffer. Tat decreased MBP expression both in the CC (upper) and in the ST (middle).
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Band densitometry data are shown in the bar graph (lower). Data are expressed as
mean ± S.E.M. after normalized to β-actin shown in each gel. Note that Tat-induced
reduction of MBP expression was blocked by PAP and MgTx. Experiments were done in
triplicates. Scale bar equals 20 µm *P < .05 vs. ctrl; #P < .05 vs. Tat.
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3.4.
Having

Tat interacted with KV1.3 channel
demonstrated

the

involvement

of

KV1.3

in

Tat-induced

oligodendrocyte/myelin injury, we next sought to examine if Tat interacts directly with
KV1.3 at protein level. For this purpose, we transfected HEK293 cells with pJK/KV1.3
plasmid, followed by pull-down of GST or GST-HIV-Tat recombinant proteins (GST-Tat)
with total HEK293 cell lysates. As anticipated, KV1.3 protein was successfully overexpressed in HEK293 cells (Fig. 12A, left panel right lane) and, the recombination of
GST-Tat was confirmed by western blot (Fig. 12B right panel). KV1.3 was precipitated by
GST-Tat in lysates from HEK293 cells infected with pJK/KV1.3 (HEK/KV1.3), but not
detected in pJK-infected cells (HEK/pJK, Fig. 12A right panel), suggesting Tat was
associated with KV1.3 in HEK293 cells. The association of Tat and KV1.3 proteins was
also detected in rat brain homogenate by the GST pull-down assay. As showed in Fig.
12B (upper left), KV1.3 was detectable in precipitated fraction of rat brain with addition of
GST-Tat but not in fraction with GST per se, suggesting that Tat interacts with KV1.3 in
rat brain tissue as well.
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Figure 12. Tat interacted with KV1.3 protein. GST-Tat recombinant protein was added
to pJK-KV1.3 transfected HEK293 whole cell lysate or rat brain tissue homogenate for
protein pull-down assay. Panel A, Tat interacted directly with KV1.3 expressed in
HEK293 cells. Left in panel a is representative blot results showing KV1.3 protein was
successfully overexpressed in HEK293 cells transfected with pJK-KV1.3 (HEK/KV1.3)
plasmids. Right in panel a shows pull-down assay demonstrating that Tat can interact
with KV1.3 protein overexpressed in HEK293 cells. Shown in Panel B are the pull-down
results illustrating GST-Tat interacts with KV1.3 protein in rat brain tissue lysates (left).
The expression of KV1.3 in rat brain is showed in the lower left. Right in panel b shows
the bands of GST (lower bands) in both GST and Tat band (upper band) only in GST-Tat.
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3.5.

Tat enhances oligodendrocyte KV1.3 current by retarding channel

inactivation and downregulation of channel protein phosphorylation
Alterations in the current density of ion channels are generally attribute to three
possible factors: changes in channel expression, promotion of channel translocation, or
modification of channel kinetic activity. We next investigated the impact of Tat on
oligodendrocyte KV channel kinetics of voltage dependency, which is feasible to cause
current change in 2 h. Primary oligodendrocytes were treated with 50 ng/ml Tat for 2 h
before recording, and whole cell K+ currents were recorded before (Tat) and after
addition of 5 nM MgTx to the bath solution (MgTx + Tat) for 20 min. Tat did not shift the
activation curve of oligodendrocyte K+ currents (V1/2 = 21.52 ± 4.19 mV of control cells
and V1/2 = 20.93 ± 4.55 mV of Tat-treated cells, p > .05), however, the inactivation curve
shifted to the right after Tat treatment and, the shift was fully counteracted by MgTx (Fig.
13A). This data suggest KV1.3 is primarily involved in the Tat-induced inactivation shift of
oligodendrocyte K+ currents and, Tat may cause more slowly inactivation of
oligodendrocyte KV1.3.
It is known that KV1.3 channel contains several regulatory tyrosine phosphorylation
residues at N- and C- terminus, as well as p-loop [194, 195]. Tyrosine kinases
phosphorylate KV1.3 at these residues that cause channel inactivation, which is an
important mechanism of KV1.3 activity regulation. We confirmed the channel
phosphorylation by interaction of KV1.3 and tyrosine kinase p-Src (Fig. 13D), which is
similar with previous findings that Src kinase phosphorylates KV1.3 cause current
suppression [196, 197]. Combined that Tat affects the channel inactivation, we next
determined the possibility that Tat changes the KV1.3 kinetics by disturbing the tyrosine
kinase-mediated KV1.3 phosphorylating regulation. Pervanadate (PVD), a universal
tyrosine phosphatase inhibitor, was introduced to evaluate whether Tat intervenes
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channel phosphorylation. PVD performed to enhance channel phosphorylation thus
sustain channel in inactive status. PVD was prepared freshly in prior to use by mixing
sodium orthovanadate with H2O2 as described previously [179]. The oligodendrocytes
were treated with 50 ng/ml Tat for 2 h. Currents were recorded at control and Tat-treated
cells before and after application of PVD to bath solution at the working concentration of
200 µM for 10 min. The shift of inactivation curve caused by Tat was neutralized by PVD
(Fig. 13B), suggesting that Tat hinder channel inactivation by disturbing tyrosine kinasemediated channel phosphorylation. To confirm the phosphorylation-mediated inactivation
shift is contributory to the current enhancement, the outward K+ current density was also
determined with presence of PVD. Tat increased the total outward K+ currents in
oligodendrocytes as expected and, the increase was counteracted by application of PVD
into the bath (Fig. 13C).
So far, we have addressed that the modification of channel kinetic activity is
causative to enhanced KV1.3 currents. In addition to the phosphorylating regulation and
protein-protein interaction, the potential translocation of KV1.3 channels from cytoplasm
to plasma membrane can also induce the KV1.3 current increase in 2 h. We isolated the
oligodendrocytes proteins to cytosol- and membrane- sections by membrane protein
extraction kit (Biovision Incorporation), then the expression of KV1.3 in each section was
evaluated before and after treatment with 50 ng/ml Tat for 2 h. Tat increased the
expression of KV1.3 in cytosol section but no significant increase in membrane section
(Fig. 14), suggesting translocation is not contributory to detected KV1.3 current
enhancement.
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Tat
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KV1.3

channel

inactivation

and

channel

phosphorylation regulation. For inactivation analysis, recoded cells were held at -80
mV during voltage-clamping. K+ channels were pre-activated by voltage steps from the
potential -150 mV to 60 mV with 15 mV increments and then tested at the depolarization
pulse of 40 mV. Normalized data points were fitted with the Boltzmann equation:
I/Imax=1/{1+exp[(V-V1/2)/k]}. Panel A, Fitted inactivation curve of each group as indicated.
N = 8 of each group. V1/2 of Tat was -57.99 ± 2.23 mV compared with -62.39 ± 1.79 mV
in Ctrl; and V1/2 was -66.41 ± 2.03 mV with presence of MgTx.

Panel B, Fitted
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inactivation curves of each group as indicated. n = 6 of each group. V1/2 of Tat was 49.06 ± 2.62 mV compare with -66.32 ± 1.46 mV of Ctrl. V1/2 of Tat-PVD was -65.01 ±
4.53 mV compare with -66.60 ± 3.78 mV of Ctrl-PVD. Panel C, Mean of I-V curve of
peak K+ current density of n = 6 of each group. ** p < .01 vs. Ctrl. Panel D,
Representative blot shows the co-immunoprecipitation by application of KV1.3 primary
antibody into rat brain homogenate and immunoblotted by p-Src antibody. The
expression of p-Src in rat brain is showed in the left. Right lane shows the bands of pSrc pulled down by KV1.3 antibody.
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Figure 14. Tat did not promote KV1.3 translocation in 2 h. Cells were treated with 50
ng/ml Tat for 2 h. Proteins were separated to cytosol (Cyto) and membrane (Memb)
fraction. Panel A, representative blot of KV1.3 immunoreactivities. Panel B, data are
normalized to β-actin. Data were obtained from 3 independent experiments. *p < .05,
N.S. non-significant.
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4. Discussion
It is widely believed that HIV-1 persists in the brain despite of cART. The virus
persistent in a latent or restricted manner in monocyte-macrophages, microglia and
astrocytes continues to play a significant disease-inciting role. Indeed, HAND remains a
subcortical dementia with notable evidence of affected white matter tracts within the
corpus callosum, internal capsule and superior longitudinal fasciculus [8, 82, 91]. How
HIV-1 brain infection causes white matter damage is not fully understood. In the present
study, we investigated the effects of HIV-1 protein Tat on oligodendrocytes, the myelinforming cells in the CNS. Our results demonstrated that Tat induces oligodendrocyte
injury via activation of voltage-gated K+ channel KV1.3. Such an effect can be blocked by
knockdown of KV1.3 gene or by specific KV1.3 antagonists MgTx and PAP, but not by
GxTx, a specific KV 2.1 antagonist, suggesting an involvement of KV1.3 in Tat-induced
oligodendrocyte injury. Further studies revealed that Tat interacts with KV1.3 at protein
level, resulting in a prolonged channel activation via a decrease of tyrosine
phosphorylation of KV1.3 channel.

These results, to our knowledge, are the first

demonstrations that Tat induces oligodendrocyte injury via KV1.3.
The consensus view regarding HAND pathogenesis has been related to cerebral
white matter damage [41, 198]. Many cellular and viral factors are involved in HIV-1associated brain white matter damage. Amongst them is viral protein Tat. It has been
shown that Tat continues to be detectable in the CSF of HIV-infected patients with wellcontrolled viremia in the cART era [199]. With a broad range of actions on promoting
inflammation and producing cytotoxic stress to various types of cells in the CNS [136],
Tat might continue playing an important role for HIV-1-associated white matter damage
in the cART era. Indeed, Tat has recently been shown to act on oligodendrocytes with a
detrimental consequence [9, 12]. In an agreement with the aforementioned findings, our
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in vitro studies revealed that Tat had a direct toxic effect on the oligodendrocytes in an
oligodendrocyte primary culture system (purity > 85%) (Figs. 7, 8, 9). The detrimental
effect of Tat on oligodendrocytes was validated on ex vivo studies that treatment of rat
brain slices in culture with Tat produced myelin damage and a reduction of MBP
expression in corpus callosum and striatum (Fig. 10). Combined with the results of
increased apoptosis (Figs. 8 and 9), the reduction of MBP expression may reflect a
decrease of oligodendrocyte cell numbers. These results may explain, at least in part,
why anti-inflammatory therapies did not achieve a great benefit in HAND patients [200].
However, Tat was found to increase oligodendrocyte cell numbers in the hilus of the
dentate gyrus in a study on rats with intrahippocampal injection of Tat [47]. The
discrepancy may be caused by potentially inclusion of the population of immature
oligodendrocytes in that study [47], since proliferation of oligodendrocyte lineage cells
could increase the probability to repair damaged myelin designedly as the response to
Tat injection in vivo.

This notion is supported by an earlier report that mild myelin

damage was associated with an increase in oligodendrocyte numbers, but the
oligodendrocyte numbers decreased as damage became more severe in HIV-1-infected
brains [90, 180]. In conjunction with a previous gross anatomical study on HIV-1-infected
brains with demyelination which detected a reduction of corpus callosum volume [8], we
posit that Tat induces mature oligodendrocyte injury, resulting in and loss of cerebral
cortical white matter. Such a pathological change is concordant with the pattern of white
matter damage observed in HAND patients.
Studies have shown that excessive cellular K+ efflux and/or intracellular K+ depletion
are common characteristics in early apoptosis [84, 201]. KV1.3 is positively associated
with apoptosis in different types of cells, including retinal ganglion cell [202],
lymphocytes [140, 203], and various cancer cells [1, 27, 174]. In agreement with these
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studies, our results showed Tat-induced apoptosis in cultured oligodendrocytes was
attenuated either by knockdown KV1.3 gene or by specific KV1.3 antagonists, but not by
a KV2.1 antagonist (Fig. 8), suggesting that Tat triggers oligodendrocyte apoptosis by
increasing K+ efflux particularly through KV1.3. Moreover, blockade of KV1.3 rescued
Tat-induced MBP reduction (Figs. 10, 11), indicating that KV1.3 is involved in HIV-1related myelin damage. However, KV1.3 inhibition only partially blocked Tat-induced
apoptosis (Fig. 8), implying that Tat may cause oligodendrocyte injury through other
mechanisms, such as targeting at glutamate receptors [9]. Myelin impairments may
cause further axonal injury related to neurodegeneration in HAND, because myelinated
axons exhibit a myelin-dependency during development [201]. Additionally, the
increased K+ efflux from oligodendrocytes in an in vivo condition may affect neuronal
function through elevating the levels of extracellular K+, instead of clearing K+ released
from neurons during axonal firings [204, 205]. An earlier study from our laboratory also
showed that blockade of KV1.3 or knockdown KV1.3 expression in microglial cells
attenuated Tat-induced microglia neurotoxic activity [141]. Taking together, these
findings indicate that activation of KV1.3 plays an important role in Tat-associated
neurotoxicity.
It has been shown that the activities of several different cloned KV channels are
suppressed after phosphorylation of the channels by both receptor and non-receptor
tyrosine kinases [206]. Indeed, there are several tyrosine residues on KV1.3 channel
protein and different combinations of phosphorylated tyrosine residues are required for
current suppression as consequences of different triggering signals [207-209]. Our GSTpull down assay results showed KV1.3 presence in GST-Tat-precipitated protein complex,
indicating a direct interaction between Tat and KV1.3 protein (Fig. 12). Such an
interaction may cause an interruption of phosphorylation regulation of KV1.3 channel.
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This notion is supported by experimental results that tyrosine phosphatase inhibitor PVD
attenuated Tat enhancement of KV1.3 currents and prevented Tat-induced right-shift of
KV1.3 channel inactivation curve (Figs. 13B and 13C). Although we did not examine
direct phosphorylation of KV1.3 channels due to the paucity of efficient antibody, our
available data (Figs. 6 and 13A) indicate that Tat may increase KV1.3 currents by
decrease of channel protein tyrosine phosphorylation and prolonged channel in
activation state as revealed by a right-shift of inactivation curve (Fig. 13A). However, the
tyrosine kinase-associated KV1.3 channel modulation can be influenced by adaptor
proteins through direct protein-protein association involving Src homology (SH) domains
[195, 210]. As Tat binds to SH3 domains of Grb2 [211], it is also possible that Tat
interacts indirectly with KV1.3 via adaptor proteins, of which Grb2 might be a potential
candidate. In addition to protein-protein interaction and tyrosine phosphorylation
regulation of KV1.3 channel activity, mobilization of cytoplasm KV1.3 channels to plasma
membrane could also be possible for underlying mechanism for Tat-induced increase of
the KV1.3 current in oligodendrocytes. We separated the oligodendrocyte proteins into
cytosol and membrane fractions by membrane protein extraction kit (Biovision
Incorporation), then the levels of KV1.3 in each fraction were evaluated. Tat increased
the levels of KV1.3 in the cytosol fraction but no significant increase in membrane
fraction (Fig. 14), suggesting the translocation of KV1.3 from cytosol to the plasma
membrane was not involved in observed Tat-associated increase of KV1.3 current in
oligodendrocytes.
It is worth pointing out that the evaluations on oligodendrocyte cell viability/apoptosis
and myelin morphology in brain slices were conducted at different time points, 48 h and
72 h, respectively. This is because, at the same concentrations, a longer time was
needed to generate significant morphological changes in brain slices than apoptotic
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changes seen in primary cell cultures. It is also worth pointing out that, in addition to its
toxic effect to mature oligodendrocytes and myelin sheaths, Tat may also induce
disturbance of myelin maintenance via KV1.3 channels, such as oligodendrocyte
progenitor cells proliferation and differentiation, leading to myelin/white matter
abnormalities as seen in the brains of HIV-1-infected patients. As basal activity of KV
channels controls oligodendrocyte proliferation and differentiation [44, 133, 212], the
alteration of KV1.3 channel activity by Tat may possibly disturb oligodendrocyte lineage
cell proliferation and differentiation, and ultimately myelin maintenance processes. In
addition, KV1.3 was shown to play a crucial role in controlling cell cycle activation [133].
This may explain why PAP-treated oligodendrocytes in our studies exhibited higher cell
viability (Fig. 7) than the control oligodendrocytes.
In summary, our present studies demonstrated that HIV-1 protein Tat induces
oligodendrocyte/myelin injury by enhancing outward K+ current conducted by a voltagegated K+ channel KV1.3 by using specific KV1.3 antagonists and siRNA knockdown of
KV1.3 gene. This is the first demonstration that Tat targets at oligodendrocyte KV1.3
channels

by

direct

protein-protein

interaction

and

interruption

of

channel

phosphorylation/de phosphorylation processes. These findings may serve not only to
elucidate the mechanisms underlying HIV-1-associated brain white matter damage seen
in HIV-1-infected patients in the era of cART, but also to provide a potential target for the
development of therapeutic strategies for amelioration of HIV/Tat-induced brain
myelin/white matter injury.
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Chapter 3

Tat impairs oligodendrocyte progenitor cell
survival and maturation
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Abstract
HIV-1-associated neurocognitive disorder (HAND) is a subcortical disease involving
neuronal loss and axonal demyelination. Myelin is deposited by oligodendrocytes
through a complex process requiring oligodendrocyte progenitor cell (OPC) proliferation,
migration, and maturation. It has been shown that OPC are susceptible to viral proteins
such as Tat and that OPC survival and maturation are defective in HAND. Studies also
have demonstrated that enhancement of voltage-gated K+ channels (KV) are involved in
regulation of OPC development. Particularly, suppression of KV1.3 currents is required
for OPC maturation. Thus we hypothesized that the HIV-1 protein Tat induces OPC
damage and hinders OPC maturation by enhancing outward K+ current conducted by
subtype KV1.3, contributing to HAND pathogenesis. To test this hypothesis, we studied
the KV1.3 expression in primary cultured OPCs and, the effect of Tat on OPC apoptosis
and maturation. KV1.3 currents and channel expression decreased within development,
while incubation of OPC cultures with Tat increased levels of KV1.3 current density and
channel expression as revealed by whole-cell patch clamp and RT-PCR. Tat induced
OPC apoptosis and decreased the number of mature oligodendrocyte and, these Tatcaused changes were prevented by 5-(4-phenoxybutoxy) psoralen, a specific KV1.3
blocker. Our results suggest that Tat induces OPC apoptosis and maturation deficit
through KV1.3, indicating KV1.3 as a potential target for the development of therapeutic
strategies for HIV-associated myelin injury.
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1. Introduction
Infection with HIV-1 remains a persistent and even growing health problem
worldwide. HIV-1 invades the CNS early in the course of infection and provokes
progressive cognitive behavioral and neurological impairments, collectively referred to as
HIV-1-associated neurocognitive disorder (HAND) [1]. With the advent of combination
antiretroviral therapy (cART), the number of severe HAND patients has decreased.
However, due to a longer lifespan and drug toxocity, it is becoming apparent that
patients suffer from protracted infection may exhibit more subtle forms of mental
impairment of which myelin injury is one of the main causes [213]. Brains of HIV-1infected patients show pathological changes in the corpus callosum, which is associated
with a significant decrease in nerve numbers and fiber density, as well as the impaired
outer contour and decreased thickness of each single myelin sheath [8]. Because HAND
remains highly prevalent and continues to be a significant epidemiological problem,
research into the molecular and cellular mechanisms of HIV-induced myelin injury and
axonal damage is pressing.
Myelination, formed by oligodendrocytes in the CNS and Schwann cells in the PNS,
is achieved by extending oligodendrocyte plasma membrane processes to enclose
axons leading to formation of myelin sheath, which is an insulating sheath essential for
saltatory propagation of electrical signal along axonal. The process of repairing
damaged myelin is remyelination, which is required to maintain the myelin homeostasis
and repair damage of myelin injury or loss. Remyelination involves proliferation and
survival of oligodendrocyte progenitor cells (OPC), migration of OPCs to the damaged
area, and maturation of OPC to mature myelinating oligodendrocytes [214]. In HIV-1
infected brains, mild myelin damage is associated with an increase in oligodendrocyte
number, although the number decreases with severe damage [90]. In agreement, the
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mRNA level of transcription factor Olig2, a marker with higher expression in OPC and
lower expression in mature oligodendrocytes [91], is elevated in the front cortex of HIV1-infected patients [48]. These results indicate that OPC proliferate to repair damaged
myelin sheath in response to HIV infection. Thus, we hypothesize that differentiation of
OPCs into post-mitotic oligodendrocyte might be a major check-point for myelin
maintenance and repair in HAND.
Although the viral load is minimal in the nervous system, the transcription and
release of viral proteins, such as Tat, from early infected cells continues over the course
of infection [174]. Tat is a required transcription factor for HIV-1 gene expression. Tat
has been linked to progressive development of HAND impairing the integrity of blood
brain barrier [203, 215], activating microglia to behave cytotoxic and pro-inflammatory
effects [198], and direct toxicity on neuronal cells [216]. Detection of Tat has been
demonstrated in both viral-infected and uninfected oligodendrocytes in the brain of AIDS
patients may due to its penetrability of plasma membrane [10]. Oligodendrocytes are
susceptible to HIV-1 Tat protein involving the activation of Caspase-3 [12]. Because viral
protein transcription continues while viral load is well controlled by cART [174, 217], Tat
toxicity of oligodendrocyte may contribute to the fact of increased population of milder
HAND in cART era.
The KV channel family is the largest and a rapidly-expanding family of ion channels
that are associated with signaling pathways required for cell survival and physiological
activities. Accumulating evidence indicate that modulation of KV channels is a new
approach to regulate OPC/oligodendrocyte activity. Generally, KV expression in
oligodendrocyte lineage cells correlates with differentiation stages. Currently, the KV1
subfamily is mostly studied in oligodendrocyte. KV1.3 [129, 130], KV1.5, KV1.6 [129], and
inward rectified K+ channel 4.1 [131, 132] play crucial roles in regulation of OPC
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proliferation and maturation. In particular, KV1.3 channels play a crucial role in G1/S
transition of proliferating OPCs [130, 133]. In addition, Kv1.3 controls cell cycle activation
by affecting a component, C5b-9-mediated activation of AKT, thus mediate
oligodendrocyte dedifferentiation [133]. However, the role of KV1.3 in regulation of HIVinduced OPC maturation retardation is not fully understood. The present study
demonstrates Tat hinders OPC differentiation and induces OPC apoptosis by increasing
KV1.3 currents, thus interrupting the myelin maintenance and/or remyelination related to
HAND pathogenesis.
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2. Materials and methods
Information of Tat and animals, experimental procedures of OPC culture,
electrophysiology, Western Blotting, immunofluorescence, MTT assay, and Tunel assay
are same as described in Chapter 2 Materials and method section, unless otherwise
complementarily described below.
2.1.

Electrophysiology. The resting membrane potentials were determined by

zero-current

potential

measured

shortly

after

achieving

whole-cell

recording

conformation. The cell capacitances were read under the membrane-test function.
Current amplitudes were measured at the peak and at 300 ms for each test potential.
These currents correspond to the transient A-type outward K+ current (IA) and delayed
rectified K+ current (IK), respectively.
2.2.

RNA extraction. Total RNA isolation was achieved by Trizol reagent

(Invitrogen, Carlsbad, CA). Chloroform, isopropyl alcohol and 75% ethanol (in RNasefree water) were all from sigma. RNase-free water was from Promega (Madison, WI).
OPCs were washed twice with sterile cold PBS. Trizol was provided at 1 ml to each
well of cultures in 6-well plates. Cells were lysed by passing several times through a
pipette. The lysate was collected in freshly-sterilized 1.5-ml tubes and then incubated for
5 min in room temperature. Each tube received addition 0.2 ml of chloroform and then
was capped securely. Tubes were shaken vigorously by hand for 15 seconds and
incubated in room temperature for 3 min. Samples were centrifuged at 12,000 g for 15
min at 4 °C. The samples were then separated into 3 phases after centrifugation: lower
red phase, protein-enriched interphase, and a colorless upper aqueous phase that
contained RNA. Approximately 0.5 ml of the upper phase of each sample was carefully
transferred into fresh tubes. The same amount of 0.5 ml of isopropyl alcohol was added
to each tube to precipitate the RNA. Samples were incubated at room temperature for 10
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min. Centrifugation was then performed at 12,000 g for 10 min at 4 °C. The RNA
generally formed a gel-like pallet at the bottom of tubes. The supernatant was removed
and, 1 ml 75% ethanol was added to each tube to wash the RNA. Samples were
preceded to vortex and centrifuged at 7,500 g for 5 min at 4 °C.
The RNA isolation was finally achieved by discarding the supernatant and drying the
pallet in room temperature for about 5 min. RNA was dissolved in 12 µl RNase-free
water by passing them through a pipette. The amount of 2 µl RNA of each sample was
taken for RNA concentration determination. The rest was stored at -80 °C for further
reverse transcription. RNA concentration was determined by Nanodrop 2000.
2.3.

Reverse transcription-PCR. Reverse transcription was accomplished with a

SuperScript III first-strand synthesis kit (Invitrogen). The amount of 2 µg of each RNA
sample was taken and balanced the volume of to 8 µl by RNase-free water for every
sample, followed by addition of 1 µl oligo-dT primer and 1 µl dNTPs to each sample. The
cDNA synthesis mix was prepared in a separate tube by mixing 2 µl of 10 × RT buffer, 4
µl of 25 mM MgCl2, 2 µl of 0.1 M DTT, 1 µl of RnaseOUT, and 1 µl of SuperScript III RT
(10 µl total) for each sample. The prepared mix was kept on ice.
The sample (RNA + primer + dNTPs) was projected onto the thermal plate of PCR
machine (Eppendorf RealPlex2). The program was set as 65 °C for 5 min, pause, 50 °C
for 50 min, 85 °C for 5 min, pause, 37 °C for 20 min, hold at 4 °C. After reverse
transcription program started, the samples were taken out at the first pause and placed
on ice for at least 1 min. Prepared cDNA synthesis mix (10 µl) was added to each
sample. At the second pause, 1 µl of RNase H was provided for each sample.
Reactions containing cDNA from reverse transcription, unique primer pairs and PCR
master mix 2× (Promega) were systematically performed for PCR amplification. Primer
sequences were designed according to the rat cDNA: KV1.3 forward primer, GTA CTT
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CGA CCC GCT CCG CAA TGA, reverse primer, GGG CAA GCA AAG AAT CGC ACC
AG; GAPDH forward primer, TCA AGA AGG TGG TGA AGC AG, reverse primer, AGG
TGG AAG AAT GGG AGT TG. PCR cycles were performed as follows: initial 5 min at
95 °C, then 30 cycles of 95 °C (15 s), 55 °C (30 s), and 72 °C (45 s), followed by 10 min
at 72 °C for completion of extension.
2.4.

Statistics. All data are expressed as mean ± S.D. unless otherwise indicated.

Statistical analyses were performed by student`s t test or one-way ANOVA followed by a
Fisher`s least-significant difference test for multiple comparisons. The difference
between groups was considered significant at p < .05.
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Tunel/PCR

Figure 15. Scheme of experimental treatments.
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3. Results
3.1. Developmental changes of OPC/oligodendrocyte resting membrane
properties
Whole-cell voltage-clamp studies were performed on cells that had been cultured 1221 d (2-11 d after isolated from mix glial culture). In order to avoid electrical coupling
between adjacent cells, the investigations reported in the present study were confined to
cells that extended processes but did not contact with neighbor cells. Table 1 lists
resting membrane potential and membrane capacitance that were observed during
development in OPC/oligodendrocyte culture. Generally, the resting membrane potential
changed toward negative within time during OPC development. However, resting
membrane potential of mature MBP+ oligodendrocytes remained similar compared with
late GalC+ OPCs. Membrane capacitances were larger in GalC+ and MBP+ cells than
those in NG2+ OPCs. The membrane capacitances varied from 7.05 pF in a cell had
bipolar morphology to 25.40 pF in a cell that developed multiple processes.
3.2. K+ currents in oligodendrocyte lineage cells at different developmental
stages
To investigate the activity of KV channels in oligodendrocyte lineage cells, whole-cell
K+ currents in OPCs/oligodendrocytes were recorded at different developmental stages.
OPCs were recorded at three ages. Early stage of NG2+ OPCs were recorded at 14 d
and 17 d (NG2+ 14 d, NG2+ 17 d) respectively. Late stage of GalC+ OPCs were recorded
at 19 d (GalC+). MBP+ cells were recorded at 21 d to represent mature oligodendrocytes
(MBP+). At an early stage of 14 d, NG2+ cells expressed relatively high level of outward
K+ currents. However, the current density of IA was decreased by 44% as the cells
differentiated to MBP+ oligodendrocytes. In contrast, IK did not show significant changes
during OPC development (Fig. 16).
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Table 1 Resting membrane properties of OPCs/oligodendrocytes

Cell marker
NG2+

GalC+
MBP+

Cell age (d)
12
13
14
15
16
17
18
19
21

Resting membrane
potential (mV)
-49.89 ± 16.10
-47.06 ± 11.60
-54.33 ± 12.10
-60.02 ± 10.89
-64.62 ± 5.71
-65.57 ± 5.92
-66.47 ± 3.87
-67.37 ± 2.24
-65.30 ± 12.56

Capacitance
12.23 ± 2.01
11.34 ± 3.48
15.74 ± 4.76
13.78 ± 2.80
13.92 ± 3.70
15.06 ± 3.67
17.44 ± 4.50
18.52 ± 6.49
19.93 ± 5.76

n
10
10
16
9
9
15
21
16
16
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Figure 16. Developmental changes of whole-cell K+ currents in oligodendrocytes.
Panel A, representative current traces recorded during depolarizing and hyperpolarizing
pulses are shown in 14 d NG2+ cells (NG2+ 14 d, n = 16), 17 d NG2+ cells (NG2+ 17 d, n
= 15), GalC+ cells (GalC+, n = 8), MBP+ cells (MBP+, n = 15). To record total currents,
cells were held at -80 mV and pulses were applied to various test potentials for 300 ms
as shown in the upper voltage-clamp protocol (not proportional to the current traces in
duration). IA was eliminated by holding the membrane potential at -40 mV to record IK, as
shown by the clamp protocol in the second row. IA was derived by a subtraction of IK
from total K+ current and mean data are summarized in panel C. Current density-voltage
relationship of IK (B) and IA (C) in each group. ** p < .01 NG2+ 14 d vs. MBP+ at +60 mV
voltage steps.
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3.3. Involvement of KV1.3 in Tat-induced K+ current enhancement
It is known that KV1.3 is expressed at both mRNA and protein levels in OPCs and
contributes to the generation of the IA component [130]. By giving that gradual decrease
of outward K+ currents within maturation, we next determined if KV1.3 is responsible for
the observed change in outward K+ currents. The mRNA expressions of KV1.3 at
different developmental stages and the effect of Tat on KV1.3 expression were examined
by RT-PCR. At the three tested stages, KV1.3 expression was highest in 14 d NG2+
OPCs and the expression decreased within development. However, application of Tat to
OPC culture for 48 h increased KV1.3 expression in OPCs compared with that in same
age of OPCs (17 d NG2+ OPCs, Fig. 17). Corresponding results of KV1.3 currents were
revealed by electrophysiological studies. The specific KV1.3 blocker, PAP, was used to
isolate KV1.3-conducted K+ currents in OPCs by subtraction (as described in Chapter 2).
KV1.3 currents decreased within development in late OPCs compare with the early NG2+
OPCs at 14 d (78.31 ± 16.42 of NG2+ 14 d vs 54.86 ± 12.36 of GalC+ OPC, p < .05).
Treatment of 50 ng/ml Tat for 2 h increased KV1.3 currents (114.97 ± 22.35) compared
with control NG2+ OPCs at 14 d (Fig. 18). These data suggest that KV1.3 is involved in
the decrease of total outward K+ currents during development and Tat increased KV1.3
expression and currents.
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#

Figure 17. Effect of Tat on OPC KV1.3 mRNA expression. Cells were collected at
different ages as indicated. For Tat-treated OPCs (Tat-NG2 17 d), Tat was applied to
culture at 15 d for 48 h and then OPCs was collected at 17 d. Data represent results
from three independent experiments. Panel A, representative gel demonstrating mRNA
expression of KV1.3. Band densities were normalized to GAPDH and summarized in
panel B. KV1.3 mRNA expression decreased in NG2 17 d and GalC cells compare with
NG2 14d. Tat up-regulated KV1.3 mRNA expression in NG2 17 d cells. * p < .05, # p
< .05 vs NG2 14 d, ## p < .01 vs NG2 14 d.
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Figure 18. Developmental change of KV1.3 currents and alteration caused by Tat.
Data are shown for OPCs cultured for different days as indicated. Tat was applied to 14
d OPCs for 2 h in prior of recording (Tat-NG2+ 14 d). After recordings were obtained in
normal bath solution, 10 nM PAP was perfused into the cell chamber. KV1.3-excluded
currents were recorded at 20 min after perfusion. Isolated KV1.3 currents were obtained
by subtraction of KV1.3-excluded current from total current. Panel A shows
representative current traces. The voltage protocol used to generate K+ is shown in inset.
Panel B summarizes the KV1.3 current density at +60 mV. n = 6 of each group. * p < .05,
# p < .05 vs NG2 14 d.
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3.4. KV1.3 involved in Tat-induced OPC apoptosis and maturation retardation
Although the typical cells in brain infected by HIV-1 are microglia in the CNS [218], a
recent report has shown that Tat decreases OPC cell viability [9]. As previously noted,
Tat has been detected in serum and CSF at a concentration between 2-40 ng/ml in HIV
patients, however, this concentration could be under-estimated in local tissue [184, 185].
Since Tat cause oligodendrocyte apoptosis through KV1.3, we sought to determine if Tat
cause OPC apoptosis at a similar manner. To explore the effect of Tat on OPC
apoptosis and the involvement of KV1.3 channels, Tat was applied to 15 d OPCs at a
dose of 50 ng/ml with (PAP + Tat) or without (Tat) pre-addition of PAP (1 h) for 48 h.
Apoptosis was assessed at the OPC age of 17 d by Tunel staining. Exposure of OPCs to
50 ng/ml Tat increased the percentage of apoptotic cells by approximately 2-fold over
non-treated control (Ctrl) and such an increase was prevented by PAP (Fig. 19).
As noted in the introduction to Chapter 1, maturation of OPCs to oligodendrocytes is a
challenge point for myelin maintenance and remyelination in HAND. Besides Tatinduced OPC toxicity, alterations in OPC maturation is potentially contributory to
observed myelin damage in HAND. We examined whether Tat hinders OPC maturation.
GalC+ OPCs were treated with 25 ng/ml Tat, which is the dose did not cause OPC
apoptosis (Data not shown), while transferring cells into differentiating medium with or
without pre-addition of PAP (1 h). After 48 h, the cells in differentiating medium (Ctrl),
differentiating medium contained Tat (Tat), and differentiating medium contained PAP
and Tat (PAP + Tat) were projected to maturation analysis. The maturation was
determined by percentage of MBP+ cells and NG2+ cells as revealed by
immunofluorescence. Tat dramatically decreased the population of MBP+ cells from
90.91% ± 21.18% (Ctrl) to 44.44% ± 8.92% (Tat), and sustained more cells in NG2+
OPC status (48.15% ± 8.62% of Tat vs 6.06% ± 3.87% of control). Pre-treatment of PAP
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partially prevented the MBP+ cell number decrease, suggesting Tat induce OPC
maturation defects through KV1.3.
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Tunel/Dapi

Figure 19. Involvement of KV1.3 in Tat-induced OPC apoptosis. 10 nM PAP was
added to the NG2+ OPCs at 15 DIV for 1 h, followed by application of 50 ng/ml Tat (PAP
+ Tat) for 48 h. In a subset of cultures, 50 ng/ml Tat (Tat) or 10 nM PAP (PAP) alone
was added to culture media for 48 h. Panel A shows Tunel staining (green) to identify
apoptotic cells. Intact cell nuclei were visualized with Dapi (blue). Mean data are from 10
fields of each treatment from 3 independent experiments. Apoptotic percentage of each
group is summarized in panel B. Tat increased OPC apoptosis, which was prevented by
pre-addition of PAP. * p < .05 vs. control (Ctrl); #P < .05 vs. Tat. magnification was 400 ×.
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Figure 20. Suppression of KV1.3 prevented Tat-induced maturation retardation.
While OPCs being transferred to differentiating medium at 19 DIV, PAP was pre-applied
to OPC for 1 h, with (PAP + Tat) or without (PAP) following co-presence of 25 ng/ml Tat
for 48 h. In a subset of cultures, cells were in parallel transferred in normal differentiating
medium (Ctrl), or differentiating medium contained 25 ng/ml Tat (Tat). Panel A,
representative fields show MBP staining (green) an NG2 staining (red) result as a
measurement of OPC maturation, with cell nuclei visualized using Dapi stain. 10 visual
fields were analyzed for each of three independent experiments. Panel B, Tat induced
MBP+ cell number decrease was prevented by PAP. ** p <.01 vs. control (Ctrl); # p <.05
vs. Tat group; magnification was 400 ×.
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4. Discussion
Presently we show that the HIV trans-activator Tat induces OPC injury and hinders
OPC maturation using a mechanism involving KV1.3. There are two novel findings: 1)
direct induction of OPC apoptosis by HIV Tat, which is independent of the immune
system, and 2) KV1.3 channels play an essential role in Tat-induced OPC apoptosis and
maturation retardation.
In this study, we described the resting membrane properties of decreased resting
membrane potential and capacitance of OPCs as well as the total K+ currents within
development. The developmental IA declining in OPCs was accompanied with the
decrease of KV1.3 mRNA expression (Fig. 17) and decreased KV1.3 currents (Fig. 18).
This finding is similar with results previously reported that outward K+ currents are larger
during early stages of development [129, 130, 219, 220]. Moreover, the subtracted
current traces shown in Fig 18 imply that KV1.3 is transient-activated, which corresponds
to IA currents. These data suggest the regulation of KV1.3 expression is at least partially
responsible for the IA changes during development (Fig. 17). However, the resting
membrane potential becomes more negative within time, indicating that KV1.3 is not a
primarily contributory to the maintenance of OPC resting membrane potential. Previous
study demonstrated the resting membrane potential did not alter in oligodendrocytes at
the age from 1-14 d in primary culture [155]. The discrepancy between this early result
and ours is uncertain. However, it may due to the different animal model and culture
conditions. Their works were done in GalC+ oligodendrocytes isolated from the lamb
brains and cultured in DMEM supplemented with 20% horse serum, whereas ours were
isolated from rat brains and cultured in medium as described in Method. In addition, the
Na+ or Ca2+ channel inhibitor was not present in recording solutions. There was no Ca2+like current observed, and Na+- current was recorded in less than 10% of the whole
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recorded cell population. It is possible that the Na+- current-expressed cells are neural
progenitor cells.
Our results show that Tat causes apoptosis in primary culture (Fig. 19), suggesting
that Tat perform direct toxicity on OPCs. These findings are consistent with research
demonstrating Tat decreases OPC cell viability by targeting at NMDA receptor [9]. The
consensus view regarding the pathogenesis of HAND is generated by direct and indirect
models as described in Chapter 1 Introduction 1.2., of which are briefly direct toxicity and
consequences of inflammatory response caused by neurotoxins secreted from infected
macrophages, microglia, or astrocytes. Most studies suggest Tat causes neuronal
function deficits predominantly by inducing CNS inflammation (indirect model) in HAND.
However, HAND patients given cART with adjunctive “anti-inflammatory” agents do not
attain greater benefits compared with those with cART only [221], suggesting
inflammation maybe not the primary factor drives HAND pathogenesis in patients on
cART. Because Tat transcription continues in these patients with good access with
cART, Tat-performed direct toxicity on OPCs provide a potential mechanism for
observed myelin damage in cART era [222]. Regarding the concept of increased efflux
of K+ in programmed cell death [84] [223], our recent research has focused attention on
the role of KV channelopathies in HAND pathology. In an earlier publication from our
laboratory, we demonstrated that blockade of KV1.3 or knockdown KV1.3 expression in
microglial cells eliminated neuronal apoptosis triggered by exposure to supernatant from
Tat-containing microglia [141]. We show that Tat exposure leads to an up-regulation of
KV1.3 mRNA (Fig. 17) expression and amplification of KV1.3 currents (Fig. 18). Tatinduced apoptosis in cultured OPCs was decreased in the presence of PAP (Fig. 19),
suggesting that Tat may trigger OPC apoptosis by amplifying K+ efflux through KV1.3
(Fig. 18, and 20).
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Controversial results have been reported in OPC cell fate in HIV-related
pathogenesis. The mRNA levels of transcription factor Olig2, which is expressed to
higher levels in OPC and lower levels in mature oligodendrocytes [91], are elevated in
the front cortex of HIV patients [48], may due to increased OPC proliferation for repairing
damaged myelin sheath in response to HIV infection. However, in another research, Tat
exposure reduces the population of Olig2+ OPCs, but progenitor survival is unaffected
[85], suggesting the proliferation was interrupted. Overall, as mentioned in Chapter 1,
HIV-1 infection or viral protein exposure appears to incline NPC fate toward production
of glia/astroglia at the expense of neurons and/or oligodendrocytes [85, 93, 94]. Thus we
hypothesized OPC maturation is the key point for myelin maintenance and remyelination
in HAND. Studies of genetically altered expression of KV channels in oligodendrocytes
suggest that basal activity of KV channels directly controls proliferation and differentiation
[183, 212]. Immunocytochemical staining of oligodendrocyte lineage cells acutely
isolated from tissue slices demonstrated that expression of KV1.3 and KV1.5 subunits
was higher in NG2+ and O4+ (late OPC maker) OPCs than in mature O1+
oligodendrocytes. In parallel, the expression of the same subunits within the NG2+, O4+,
and O1+ populations had the same pattern as that of cyclin D, suggesting that KV1.3 is
developmentally regulated with progression through the oligodendrocyte lineage [130].
Tat exposure decreases the population of MBP+ cells (Fig. 20) and KV1.3 blockade
restrain Tat-induced OPC maturation deficit, suggesting OPC maturation is impaired in
HAND and, Tat may act through KV1.3 channel to achieve dysregulation of OPC
maturation. It is worth noting that neuronal axons were not present in pure
OPC/oligodendrocyte culture; thus, we were not able to detect myelination. Maturation of
oligodendrocytes in vitro is not equal to successful myelination in vivo.
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Pathogenesis of myelin injury-related cerebral WM damage in HAND recently
attracted attention [41, 224]. HIV-1-associated myelin injury has been attributed to
effects of inflammatory response and BBB damage. However, in present study, we show
Tat directly target at OPC to cause cell apoptosis and maturation retardation; the
presence of PAP mitigates Tat-induced apoptosis and maturation retardation by
inhibiting enhancement of KV1.3 currents. Collectively, these findings serve to better
understand the myelin damage and repair processes in HAND, and support the role of
KV1.3 inhibition as a therapeutic strategy for myelin damage in HIV-1 patients.
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Chapter 4

Plasma gelsolin protects HIV-1 gp120-induced
neuronal injury via voltage-gated K+ channel
Kv2.1
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Abstract
Plasma gelsolin (pGSN), a secreted form of gelsolin, is constitutively expressed
throughout

the

central

nervous

system

(CNS).

Neurons,

astrocytes

and

oligodendrocytes are the major sources of pGSN in the CNS. It has been shown that
levels of pGSN in cerebrospinal fluid (CSF) are decreased in several neurological
conditions including HIV-1-associated neurocognitive disorders (HAND). Although there
is no direct evidence that a decreased level of pGSN in CSF is causally related to the
pathogenesis of neurological disorders, neural cells, if lacking pGSN, are more
vulnerable to cell death. To understand how GSN levels relate to neuronal injury in
HAND, we studied the effects of pGSN on HIV-1 gp120-activated outward K+ currents in
primary rat cortical neuronal cultures. Incubation of rat cortical neurons with gp120
enhanced the outward K+ currents induced by voltage steps and resulted in neuronal
apoptosis. Treatment with pGSN suppressed the gp120-induced increase of delayed
rectifier current (IK) and reduced vulnerability to gp120-induced neuronal apoptosis.
Application of Guangxitoxin-1E (GxTx), a Kv2.1 specific channel inhibitor, inhibited
gp120 enhancement of IK and associated neuronal apoptosis, similar effects to pGSN.
Western blot and PCR analysis revealed gp120 exposure to up-regulate Kv2.1 channel
expression, which was also inhibited by treatment with pGSN. Taken together, these
results indicate pGSN protects neurons by suppressing gp120 enhancement of IK
through Kv2.1 channels and reduction of pGSN in HIV-1-infected brain may contribute to
HIV-1-associated neuropathy.
Keywords: Cortical neurons; Kv channels; HIV-1gp120; Neuronal injury; Plasma
gelsolin; Neuroprotection.
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1. Introduction
Approximately

half

of

the

HIV-1-infected

patients

develop

neurocognitive

impairments [225]. With the advent of antiretroviral therapy (ART), the morbidity and
mortality resulting from HIV-1 infection has been lessened. However, the incidence of
HIV-1-associated neurocognitive disorders (HAND) continues and, due to the longer
lifespans of treated patients and ART drug toxicity, the prevalence may actually be
increasing [174, 226-228]. Although productive HIV-1 infection of neuronal cells has not
been demonstrated, it is well accepted that neurons are affected by HIV-1 through
indirect mechanisms [229-231]. These include the release of soluble neurotoxins from
HIV-1-infected and immune competent mononuclear phagocytes (perivascular brain
macrophage and microglia), leading to neuronal dysfunction and injury [229, 232]. As
noted in Chapter 1, such neurotoxins include, but not limited to, proinflammatory
cytokines, chemokines, excitatory amino acids, and viral proteins (gp120 and Tat), which
can injure or kill neurons [233]. In particular, the envelope protein gp120 has been
shown to be lethal to neurons in culture through alterations in signal transduction and
excitotoxic influx of Ca2+ [234-236]. For these reasons we chose to use gp120 to further
investigate the mechanisms underlying HAND pathogenesis in our primary neuronal
culture system.
Gelsolin (GSN) is an actin-binding protein best-known for its modulation of cell
motility and secretion, is constitutively expressed throughout the CNS and particularly
concentrated in neuronal growth cones. This protein exists in two isoforms, cytoplasmic
gelsolin (cGSN) and plasma gelsolin (pGSN) [237]. Both isoforms are functionally similar
and encoded by a single gene on chromosome 9 [238, 239]. In addition to its widely
recognized function as a cytoplasmic regulator of actin organization, accumulating
evidence suggests GSN activity prevents neuronal apoptosis in multiple ways [240],
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including through the facilitation of voltage-dependent Ca2+ channel (VDCC) and NMDAchannel rundown following exposure to excitotoxic stimuli, thereby reducing cytosolic
Ca2+ overload [241, 242]. Proteomic studies have revealed decreased pGSN levels in
CSF of HIV-infected individuals with cognitive disturbance [243]. In addition, altered
pGSN levels have been noted in other neurological conditions [244-246], such that
pGSN is being considered as a biomarker for certain neurodegenerative disorders [246248]. In general, GSN has been found neuroprotective and is now being considered as
a potential treatment modality in several diseases characterized by neuronal injury [244,
245, 248-251].
K+ channels necessarily contribute to the process of apoptosis. Regardless of the
diverse external and internal stimuli that trigger cell apoptosis, enhanced K+ efflux has
been shown to be an essential mediator of apoptotic cell volume decrease, downstream
caspase activation, and DNA fragmentation [84]. In previous experiments, our laboratory
has confirmed the association of rat cortical neuron apoptosis and increased K+ channel
currents in models of HAND [143, 144, 252]. While several Kv channel subtypes have
been implicated in cortical neuron apoptosis, including Kv2.1 [152], Kv1.1 [253], Kv3.4
[153], Kv4.2, and Kv4.4 [154], the specific subtype involved in HAND pathology and the
mechanism underlying its dysfunction remains to be definitively characterized.
Collectively, these observations lead us to investigate the protective potential of pGSN
against gp120-induced neuronal injury and to determine the function of specific Kv
channel subunits in this neuroprotective activity.
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2. Experimental Methods
2.1. Materials
HIV-1gp120 IIIB was purchased from Immunodiagnostics, Inc. (Woburn, MA).
Aliquots of gp120 were kept as 100 nM stock solution at -80 C. The stock solution was
diluted to desired concentrations with artificial cerebrospinal fluid (ACSF) 2-5 min before
test. Gelsolin (recombinant human plasma isoform) was purchased from Cytoskeleton,
Inc (Denver, CO). All chemicals, unless otherwise specified, were from Sigma-Aldrich
(St. Louis, MO).
2.2. Animals
Pregnant Sprague-Dawley rats were purchased from Charles River Laboratories
(Wilmington, MA). Animals were housed at a constant temperature (22°C) and relative
humidity (50%) under a regular light-dark cycle (light on at 7 AM and off at 5 PM) with
free access to food and water. Animal use procedures were strictly reviewed by the
Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska
Medical Center (IACUC No. 00-062-07).
2.3. Rat cortical neuron preparation and culture
Neurons were isolated from cortex tissue of E18 fetal Sprague-Dawley rats. Culture
dishes or plates were coated with poly-D-lysine (1mg/ml) for 1 h at 37 °C in prior to
primary culture. All tools were autoclaved.
Firstly, pregnant rat was anesthetized by isoflurane and, then cut through skin and
muscle with a pair of scissors to expose the uterus, intestines, and embryos. Embryos
(in amniotic sac) were taken out carefully and placed into 10 cm- petri dish filled with
cold HBSS. Embryos were taken from amniotic sac and placed to a fresh petri dish with
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cold HBSS. Next, embryos were decapitated with large scissors and the heads were
placed in a spate 10 cm-petri dish filled with cold (HBSS).
Microdissecting scissors was used to carefully cut skin and the skull along the
midline from neck toward the nose. Brain was then taken out with a spatula and placed
to another petri dish contained cold HBSS.
The meninges were removed with forceps under a dissection microscope. Cortex
tissue was dissociated by cutting the brain to two hemispheres, followed by removing
hippocampus and olfactory bulbs. The tissue was then incubated in 0.25% trypsin and
200 U DNase contained in HBSS at 37 °C for 15 min. FBS was applied to tissue
suspension to stop trypsinization and then homogenate was transferred to a 50 ml tube.
The contents were pipetted one time to separate any tissue block. The tissue
suspension was next collected into a clean 50 ml-tube and centrifuged at 1500 r.p.m for
10 min. The supernatant was removed and 20 ml DMEM was added to suspense the
remained cells/tissues by triturating cells/tissue for about 20 times. The remaining tissue
suspension was passed through nylon mesh with pore diameter size of 100 µm and 40
µm. Cells were collected by centrifugation at 1500 r.p.m for 10 min.
Isolated cells were then suspended in neurobasal media (Gibco by Life Technologies)
supplemented with 2% B27, 1% penicillin/streptomycin, 0.2% FBS, and 0.25 mM Lglutamine (Invitrogen by Life Technologies), and seeded either in 60 mm dishes at 2.5 x
106 cells/dish, 0.2 x106 cells/well in 12 well plates containing 15 mm diameter coverslips,
or in 48-well plates at 0.05 x 106 cells/well. Cultures were maintained in supplemented
neurobasal media for 8-12 days with half media change every 4 days. The purity of
neuronal cells was determined to be >90% (Fig. 21) by staining with microtubuleassociated protein-2 antibody (MAP-2: 1:1000, Chemicon International, Inc. Temecula,
CA).
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Figure 21. Purity of cortical neuronal cultures. View of neurons stained with Map2
(red).Cell nuclei are visualized wih DAPI DNA stain. Neuronal purity >90%.
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2.4. MTT assay
Cell viability was assessed by MTT assay. Neurons were cultured in 48-well plates
for MTT assay to minimize discrepancies between replicates. The MTT stock solution
was prepared in sterile PBS at concentration of 5 mg/ml (10 ×) and store at -20 °C. The
working solution was made by diluting the stock MTT solution 10 times with neurobasal
media without supplements. Pre-treated cells were exposed to 300 µl of neurobasal
media contained 500 µg/ml MTT (Sigma-Aldrich) for 2 h at 37 ºC. The MTT solution was
discarded and replaced with 150 µl dimethyl sphingosine (DMSO). Cells were then
shaken for 15 min at 200 r.p.m for completed lysis. The dissolved solution was
transferred of 100 µl from each well to a 96-well plate and, 96-well plate was eventually
placed to a plate reader and tested the optical density at 560 nm.
2.5. Tunel assay
Neuronal apoptosis was evaluated by using a Fluorescein In Situ Cell Death
Detection Kit (Roche Applied Science, Indianapolis, IN). Briefly, Neurons grown on the
poly-D-lysine-coated coverslips were washed twice with PBS and fixed in 4%
paraformaldehyde (PFA) for 1 h at room temperature. Then cells were permeabilized by
incubation with 0.1% Triton X-100 for 30 min. Cover slips were washed 5 min × 3 times
with PBS. Tunel reaction mixture was made by adding 1 part label solution to 50 parts
enzyme solution. The reaction mixture was applied onto clean Para film as 30 µl-drops
and, cover slips were flipped onto reaction mixture solution spots and incubated for 90
min at 37 °C. After washing, coverslips were mounted in vectashield mounting medium
with Dapi stain (Vector Laboratories, Burlingame, CA) and cells were visualized by a
fluorescent microscope. Apoptosis was assessed in each of three experiments by
examining 10 microscopic fields per experimental group. The percentage of apoptotic
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neurons was determined based on Tunel-positive cells normalized to Dapi-stained nuclei
in 3 independent experiments.
2.6. Electrophysiology
Whole-cell recordings were made on neurons seeded on glass cover-slips at 9-12 d.
Recording electrodes, pulled from borosilicate glass micropipettes (WPI Inc. Sarasota,
FL) with a P-97 micropipette puller (Sutter Instruments, Novato, CA), had a resistance
of 5.0–8.0 MΩ when filled with intracellular solution contained (in mM): 120 K-gluconate,
10 KCl, 5 NaCl, 1 CaCl2, 2

MgCl2, 11 EGTA, 10 HEPES, 2 Mg-ATP and 1 GTP,

adjusted pH to 7.3 with KOH. The extracellular solution was artificial cerebrospinal fluid
(ACSF) contained (in mM) 140 NaCl, 5 KCl, 2.5 CaCl2, 10 HEPES and 10 glucose,
adjusted pH to 7.4 with NaOH. Tetrodotoxin (TTX, 1µM) and CdCl2 (0.2 mM) were
added to the ACSF to block voltage-gated Na+ and Ca2+ channels, respectively. Stock
solutions of 4-Aminopyridine (4-AP) and tetraethylammonium (TEA) were prepared in
deionized water and diluted to working concentrations (4-AP 5mM, TEA 40mM) with
ACSF in order to block A-type transient outward K+ current (IA) or delayed rectifier
outward K+ current (IK). After establishment of the whole-cell patch configuration, the
cells were allowed to stabilize for 3-5 min before tests. The recorded cells were held at 80 mV during voltage-clamping. Whole-cell outward K+ currents were generated by
voltage steps from the holding potential -80mV to +80mV in increments of 20mV.
Current amplitudes were measured at the initial peak and at 300 ms and current
densities (pA/pF) were calculated by dividing the amplitudes by the whole cell
capacitance. Junction potential, pipette resistance were corrected and cell capacitance
were compensated (~70%). Current signals were filtered at 1 kHz and digitized at 5 kHz
using Digidata 1440A digitizer (Molecular Devices). The current and voltage traces were
displayed and recorded in a computer using Clampex 8.2 (Molecular Devices).
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All experiments were done at room temperature (22-23°C). In prior to recording, the
bathing solution was oxygenated (bubbled with 95% O2 and 5% CO2) for 30 min. The
neuronal cells were identified by their morphology (triangular shaped) and their firing of
action potentials in response to a depolarizing current impulse. Data were analyzed by
Clampfit 8.2 (Molecular Devices) and graphed using Origin 8.5 (OriginLab, Northampton,
MA). For bar graphs illustrating current densities, the instantaneous IA and steady-state
IK generated by a voltage step from -80mV to +80mV were measured and the current
density was then calculated by dividing the current and expressed as pA/pF.
2.7. RT-PCR
The total RNA isolation was completed with Trizol reagent (Invitrogen). Reverse
transcription was performed on 1-2 µg of the RNA sample with a SuperScript III first
strand synthesis kit (Invitrogen) using the oligo-dT primers.
Pre-treated neurons were washed twice with sterile cold PBS, followed by addition of
1 ml Trizol to each well of culture in 6-well plate. Cells were lysed by passing cells
several times through a pipette. The lysate was collected in freshly-sterilized 1.5 ml
tubes and then incubated for 5 min in room temperature. Each tube received addition 0.2
ml of chloroform and was capped securely. Tubes were shaken vigorously by hand for
15 seconds, and then incubated in room temperature for 3 min. Samples were
centrifuged at 12,000 g for 15 min at 4 °C. Following centrifugation, the samples were
then separated into 3 phases: lower red phase, and protein-enriched interphase, and a
colorless upper aqueous phase that contained RNA. Approximately 0.5 ml of the upper
phase of each sample was carefully transferred into fresh tubes. The same amount of
0.5 ml of isopropyl alcohol was added to each tube to precipitate the RNA. Samples
were incubated at room temperature for 10 min. Centrifugation was then performed at
12,000 g for 10 min at 4 °C. The RNA generally formed a gel-like pallet at the bottom of
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tubes. The supernatant was removed and, 1 ml 75% ethanol was added to each tube to
wash the RNA. Samples were centrifuged at 7,500 g for 5 min at 4 °C. The RNA
isolation was finally achieved by discarding the supernatant and drying the pallet in room
temperature for about 5 min. RNA was dissolved in 12 µl RNase-free water by passing
them through a pipette. The amount of 2 µl RNA of each sample was taken for RNA
concentration determination. The rest was stored at -80 °C for further reverse
transcription. RNA concentration was determined by Nanodrop 2000.
Reverse transcription was accomplished with a SuperScript III first-strand synthesis
kit (Invitrogen). The amount of 2 µg of each RNA sample was taken and balanced the
volume of to 8 µl by RNase-free water for every sample, followed by addition of 1 µl
oligo-dT primer and 1 µl dNTPs to each sample. The cDNA synthesis mix was prepared
in a separate tube by mixing 2 µl of 10 × RT buffer, 4 µl of 25 mM MgCl2, 2 µl of 0.1 M
DTT, 1 µl of RnaseOUT, and 1 µl of SuperScript III RT (10 µl total) for each sample. The
prepared mix was kept on ice. The samples (RNA + primer + dNTPs) were projected
onto the thermal plate of PCR machine (Eppendorf RealPlex2). The program was set as
65 °C for 5 min, pause, 50 °C for 50 min, 85 °C for 5 min, pause, 37 °C for 20 min, and
hold at 4 °C. After reverse transcription program started, the samples were taken out at
the first pause and placed on ice for at least 1 min. Prepared cDNA synthesis mix (10 µl)
was added to each sample. At the second pause, 1 µl of RNase H was provided for each
sample.
The resulting cDNA was next used for PCR amplification. Primer sequences for Kv1.1
were

forward

GGAGCGCCCCCTACCCGAGAAG,

reverse

GGTGAATGGTGCCCGTGAAGTCCT, product length 191 base pairs (bp); for Kv2.1,
forward TGGAGAAGCCCAACTCATC, reverse CAATGGTGGAGAGGACATG, product
length

78bp;

for

Kv4.2,

forward

GCCGCAGCGCCTAGTCGTTACC,

reverse
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TGATAGCCATTGTGAGGGAAAAGAGCA, product length 262 bp; and for GAPDH,
forward

TCAAGAAGGTGGTGAAGCAG,

reverse

AGGTGGAAGAATGGGAGTTG,

product length 126 bp. PCR cycles were performed as follows: initial 5 min at 95°C, then
30 cycles of 95°C (15 s), 55°C (30 s), and 72°C (45 s), followed by 10 min at 72°C for
further extension.
2.8. Immunoblotting
Briefly, pre-treated neurons were washed twice with ice-cold PBS and total proteins
were extracted using RIPA (Sigma- Aldrich).
2.8.1. Total protein extraction
The whole cell lysates were prepared in RIPA buffer (BioRad, Hercules, CA) while
tissue was lysed in tissue extraction reagent (Invitrogen). In details, following
experimental treatments, neurons were washed twice with ice-cold PBS and then PBS
was aspirated. RIPA buffer supplemented with protease inhibitor (Sigma) was added
(150 µl) to each well of 6-well plate. Cells were detached by scraping the well bottom
and gently transferred into a microcentrifuge tube. Lysate was then projected to a
freeze-thaw cycle for complete lysis, and then centrifuged at 10,000 r.p.m. for 10 min
and supernatant was collected to a fresh tube. Next, 20 µl of each sample was taken out
for protein concentration determination. A quarter of the sample volume of 5 × loading
buffer was added to protein samples. Protein samples were denatured by boiling water
for 7 min, and stored in -20 °C for western blotting.
5 × loading buffer consisted of 0.25% Bromophenol blue, 0.5 M dithiothreitol, 50%
glycerol, 10% sodium dodecyl sulfate, and 0.25 M Tris-Cl (pH 6.8).
2.8.2. Protein concentration determination
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The BCA protein assay kit (ThermoFisher Scientific, Waltham, MA) was employed to
quantify protein concentration. BCA working reagent was prepared by mixing 50 parts of
BCA Reagent A with 1 part of BCA reagent B. The needed total volume of working
reagent was determined by the following equation: (number of standards + number of
unknowns) × (number of replicates) × 100 µl = total volume of working reagent required.
Standards were prepared by diluting 2 mg/ml albumin ampules in working reagent to
200, 100, 50, 25, 12.5 µg/ml. Then 100 µl of each standard was put into a 96-well plate.
At separate wells, 100 µl of working reagent only was placed as zero. Next, 10 µl of
each unknown samples was diluted to 90 µl working reagent. Every standard and
sample was duplicated. After all samples prepared, the plate was incubated in 37 °C for
30 min. The plate was then placed in a plate reader and the absorbance of all the
samples were measured with the testing wavelength at 560 nm.
Standard curve was made by plotting the average Blank-corrected measurement for
each albumin standard versus its concentration in µg/ml. The standard curve was used
to determine the protein concentration of each unknown sample. The volume for 15 µg
protein of each sample was calculated and then the denatured samples were projected
to Western blotting.
2.8.3. Western blotting
Solutions of 10 × Tris/glycine buffer, 10 × Tris/glycine/SDS buffer, 10% SDS, and 30%
Acrylamide/bis solution were all purchased from Bio-Rad. The 10 × TBS (Tris-buffered
saline, 1 liter) was prepared by dissolving 24.2 g Tris base, 80 g NaCl in distilled water,
and adjust pH to 7.6 with HCl. Washing buffer was prepared by diluting 1 ml 100%
Tween-20 to 1 liter 1× TBS (TBST).
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Proteins were firstly separated by electrophoresis depending on the molecular weight.
In details, 15 µg protein of each sample was loaded onto 10% SDS-polyacrylamide gels.
Electrophoresis was run under 70 mV constant voltage and switched to 110 mV when
samples enter lower separating gel. Electrophoresis was stopped when the
Bromophenol blue reached the bottom edge of SDS-polyacrylamide gel.
After electrophoresis, proteins were transferred from gel to a polyvinylidene difuoride
(PVDF) membrane by 100 mV constant voltage in 1 × Tris/glycine/SDS buffer containing
20% methanol for 70 min at 4 °C. The PVDF membrane was then blocked in 5% non-fat
milk in TBS for 1 h in room temperature. Following blocking, membranes were incubated
at 4 °C overnight in primary antibodies including rabbit polyclonal KV1.1 (1.500), mouse
monoclonal KV2.1,(1:500) (Abcam Inc. Cambridge, MA), rabbit anti-KV4.2 (1:200,
CHENICON International, Inc. ), anti-mouse β-actin (1:5,000), or anti-rabbit GAPDH
(1:5,000) to detect Kv1.1, Kv2.1, Kv4.2, GAPDH, and β-actin protein. Afterwards,
membranes were washed in TBS with 0.2% Tween (TBS-T) and incubated with either
HRP-conjugated onto rabbit or anti-mouse secondary antibody (1:10,000, Haacson
ImmunoResearch Laboratories, West Grove, PA) for 1 h at room temperature. Finally,
membranes were washed and visualized by Pierce ECL Western Blotting Substrate
(Thermo Scientific, Rockford, IL). Band densities captured by ImageJ.
2.9. Statistical analyses
All data were expressed as mean ± S.E.M. unless otherwise indicated. Statistical
analyses were performed by one-way ANOVA or two-tailed t test. The difference
between groups was considered significant when p < .05.
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3. Results
3.1.

gp120-induced neuronal toxicity was protected by pGSN

Neuron is not the primary cell type HIV-1 target at in brain [218]. However, viral
envelope glycoprotein gp120 has been demonstrated to induce neuronal apoptosis in
cell cultures [234, 235]. Further, while pGSN has been shown to be protective against
excitotoxic insults [241], it is detected at significantly lower levels in the CSF of HIV-1infected individuals who exhibit neurocognitive disorder [243, 254]. In light of these
findings, we sought to determine the effect of pGSN on gp120-induced neuronal toxicity.
First, rat cortical neuronal cultures were prepared and incubated for 24 h with varying
concentrations of gp120 (0-1000 pM). Neuronal viability was then assessed by MTT
assay and found to diminish significantly at gp120 concentrations above 250 pM (Fig.
23A). Given the nearly 40% loss of viability at concentrations of and greater than 500 pM,
the concentration of 500pM was utilized in neurotoxicity experiments. Next, neuronal
cultures were treated for 24 h with 500 pM gp120 and different concentrations of pGSN
(0-2500 ng/ml). pGSN was found to be significantly protective against gp120-induced
toxicity at a concentration of 2.5 µg/ml (Fig. 23B).
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Figure 22.GSN protection of gp120-induced neuronal damage. Panel A, Dosedependent toxicity of gp120 on cortical neurons. Exposure of neuronal cells to gp120 at
and greater than 500 pM resulted in maximal reduction in cell viability. Panel B, neurons
were treated with different concentrations of GSN or with 500 pM gp120 for 24 h. pGSN
protected neurons from gp120-induced damage at 2.5 µg/ml. Heat (boiled) inactivated
pGSN (indicated by a symbol §, the same as in other figures of Chapter 4) failed to
produce protective effect. Data represent means ± S.E.M. from at least 5 independent
experiments and expressed as % of control. * p < .05 vs. control, ** p < .01 vs. control; #
p < .05 vs. gp120 (0 GSN).
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3.2.

pGSN attenuation of gp120 increase of outward K+ current

It has been shown that activation of neuronal Kv channels is involved in neuronal
dysfunction and apoptosis [139, 255]. In HIV-1 infection, secreted cellular and viral
products can increase Kv channel activity, leading to neuronal dysfunction and cognitive
deficits [145]. Specifically, previous experiments in our laboratory have demonstrated
gp120 can induce apoptosis by enhancing 4-AP-sensitive IA current via PKC signaling
[143]. Given the prominent role of Kv channels in mediating neuronal damage, coupled
with the protective effects of pGSN against gp120-induced neurotoxicity observed here,
we further sought to determine if the protection provided by pGSN occurs via alterations
in Kv channel activity. First, rat cortical neuron cultures were prepared and treated with
gp120 at concentrations of 50 pM or 100 pM for 24 h. Whole-cell outward K+ currents
were then recorded. As shown in Figure 23A, gp120 produced an increase of outward K+
currents. Further analyses revealed that gp120 significantly (p < .01) increased both
instantaneous and steady-state outward K+ currents at a concentration of 100 pM (Fig.
23B). Next, we examined effects of pGSN on its blockade of gp120 increase of neuronal
outward K+ currents. Neuronal cultures were treated for 24 h with either 100 pM gp120
alone or with gp120 (100 pM) and different concentrations of pGSN (0, 5, 50, 500 ng/ml).
As expected, gp120 enhanced both instantaneous and steady-state outward K+ currents
(Fig. 24).

Treatment with pGSN reduced gp120-associated increase of outward K+

currents, with a significant (p < .01) reduction of the steady-state outward K+ current at a
concentration of 500 ng/ml (Fig. 24B). Application of pGSN alone at concentrations of 5,
50 and 500 ng/ml (data not shown) or heat-inactivated pGSN (500 ng/ml, Fig. 24B) had
no significant effects on gp120 increase of outward K+ currents. These results indicate
that pGSN inhibits gp120 enhancement of neuronal steady-state outward K+ currents.
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Figure 23. Gp120 increase of outward K+ currents. Cultures were treated without or
with 50 pM or 100 pM gp120 respectively for 24 h. Panel A, representative current traces
evoked by voltage protocol (upper left, not proportional to the current traces in duration)
from three different neurons treated without (Ctrl) or with 50 pM, 100 pM gp120
respectively for 24 h. Note gp120 at 100 pM increased outward K+ currents. Current
amplification was measured at the peak for instantaneous current and at 300 ms for
steady-state current. Panel B, instantaneous and steady-state current densities
measured at +80 mV from groups of neurons treated without (Ctrl, n = 15) or with 50 pM
gp120 (n = 13), 100 pM gp120 (n = 18). Note that gp120 increased both instantaneous
and steady-state outward K+ currents at 100 pM. ** p < 0.01 vs. control.
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Figure 24. pGSN decrease of gp120 enhancement of neuronal outward K+ currents.
Panel A, representative current traces recorded from6 different neurons treated with
gp120 (100 pM) alone, or gp120 (100 pM) and different concentrations of pGSN (5, 50,
500, 500§), or untreated control. Whole-cell currents were generated by voltage steps
from the holding potential of −80 mV to +80 mV in increments of 20 mV. Both
instantaneous and steady-state outward K+ currents were measured and current
densities were calculated and displayed in Panel B. pGSN only inhibited gp120-induced
steady-state K+ current. In contrast, heat denatured pGSN lose such an inhibitory ability.
* p < .05 vs. control, ** p < .01 vs. control; ## p < .01 vs. gp120 alone.
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3.3.

Gp120 enhancement of TEA-sensitive IK was inhibited by pGSN.

Two components of outward K+ currents recorded TEA-sensitive IK and 4-APsensitive IA were recorded in neurons. Previous studies indicate certain outward K+
currents may be more involved in apoptosis [223]. In order to determine the specific
outward K+ currents enhanced by exposure to gp120 and attenuated by treatment with
pGSN, whole-cell recordings were repeated in the presence of 4-AP (5 mM) or TEA (40
mM). As seen in Figure 25, gp120 (100 pM) augmented both 4-AP-sensitive IA and
TEA-sensitive IK (Fig. 25A), while only TEA-sensitive IK was suppressed with GSN
treatment (Figs. 25A and 25C). Application of pGSN (500 ng/ml) alone did not affect the
outward K+ current amplitude or current density of either type.
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Figure 25. pGSN inhibited gp120 enhancement of TEA-sensitive IK, but not 4-APsensitive IA. Panel A shows representative total (upper), 4-AP-sensitive (middle) and
TEA-sensitive (lower) outward K+ currents recorded from neurons treated with gp120
(100 pM), gp120 (100 pM) + pGSN (500 ng/ml), pGSN (500 ng/ml) or untreated controls
(Ctrl). Panel B and C are current density-voltage relationships, illustrating GSN inhibition
of TEA-sensitive IK. pGSN alone did not affect either the 4-AP- or TEA-sensitive outward
K+ currents (P < .05). For each type of outward K+ currents, 25 neurons were recorded in
each treatment group. * p < .05 vs. control, ** p < .01 vs. control; ## p < .01 vs. gp120
group.
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3.4.

Involvement of Kv2.1 in pGSN attenuation of gp120-induced IK

enhancement
The predominant subtypes of Kv channels reported that involve in neuronal injury
and apoptosis are Kv1 [253, 256], Kv4 [257], and Kv2 [152]. In neurons, Kv1.1 and
Kv4.2 are the principal components of IA, while Kv2.1 is responsible for IK [258]. Given
our immediate findings, we postulated Kv2.1 channels to be the predominant mediator of
the neuroprotection provided by pGSN. To test this hypothesis, we utilized the Kv2.1specific inhibitor, Guangxitoxin (GxTx) [259, 260]. Control, gp120, and gp120 + pGSN
groups were again prepared as described above. During the recordings, IK was isolated
by the addition of 4-AP (5 mM) to the bath solution and its Kv2.1 contribution suppressed
by application of GxTx (50 nM). The addition of GxTx to the control group suppressed
nearly 40% of the IK component (Fig. 26B), demonstrating the contribution of Kv2.1
channels to the delayed outward K+ current in these neurons. More importantly, the
previously observed enhancements in IK induced by exposure to gp120 were absent in
the presence of GxTx, indicating the increase was comprised of current through Kv2.1
channels (Fig. 26). Lastly, the gp120-enhanced IK attenuated by co-incubation with GSN
was not further inhibited by the addition of GxTx, allowing us to infer that both may affect
IK via modulation of Kv2.1 channel activity.
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Figure. 26. Involvement of Kv2.1 in pGSN inhibition of gp120 enhancement of TEAsensitive IK. Cultures were treated for 24 h with 100 pM gp120, 500 ng/ml pGSN or
gp120 and pGSN. Panel A, representative TEA sensitive currents recorded from
neurons with treatments indicated. TEA sensitive IK was recorded in the presence of 4AP (5 mM) alone or 4-AP and GxTx (50 nM). Note that GxTx, a specific Kv2.1 channel
blocker, abolished gp120 enhancement of the TEA sensitive IK. Panel B, a summary bar
graph of current densities (n = 25) showing GxTx inhibition of gp120 increase of TEA
sensitive K+ currents generated by a voltage step from −80 to +80 mV and GxTx per se
decreased TEA sensitive K+ currents. ** p < .01 vs. control; ## p < .01 vs. gp120 group.
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3.5.

Gp120-induced TEA sensitive IK inactivation curve shift was blocked by

pGSN
The causative factors resultant in alterations of the current amplitudes of ion
channels are potentially: regulation of channel expression, promotion of channel
translocation, or modification of channel activation. To further determine the mechanism
of gp120 enhancement of IK and its inhibition by pGSN, we next investigated the impact
of gp120 and pGSN on Kv channel activation and inactivation properties. Rat cortical
neuron cultures were first prepared for whole-cell recordings as described previously. IK
current was then isolated for recording by the addition of 4-AP to the bath solution. To
characterize the steady-state inactivation behavior of IK, 400 ms pre-conditioning pulses
were applied to step the membrane potential from -120 mV to +40 mV in 10 mV
increments, followed by a 200 ms testing at +40 mV. I-V curves were then plotted and fit
using the Boltzmann equation (I/Imax=1/{1+exp[(V-V1/2)/k]}) to yield the inactivation curve
(Fig. 27A, 27B). Similarly, the activation curve was generated by applying 400 ms
depolarizing pulses to step the membrane potential from 120 to +40 mV in 20 mV
increments and fitting the I-V data using the Boltzmann equation (G/Gmax=1-1/{1+exp[(VV1/2)]/k} (Fig. 27A, 27B). Having established the IK inactivation and activation
tendencies under control conditions, cells were then perfused for 10 min with either
gp120 (200 pM) or gp120 (200 pM) + pGSN (1000 ng/ml) and recorded using the
identical protocol. Exposure to gp120 resulted in a significant right-ward shift of the
steady-state IK inactivation curve and a slight left-ward shift of the activation curve,
reflecting a greater open channel probability at a given voltage. Further, the gp120induced depolarizing shift in the inactivation curve was counteracted by pGSN coperfusion (Fig. 27B, 27C).
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Figure 27. pGSN blockage of gp120-mediated outward K+ current inactivation shift.
Panel A, the original current traces before and after the perfusion of 200 pM gp120 or
200 pM gp120 and 1 µg/ml GSN showed as above, and currents of treatment induced
after recording 10 min in the same cell as control. Normalized data points were fitted
with the Boltzmann equation: I/Imax=1/{1+exp[(V-V1/2)/k]} and G/Gmax=1-1/{1+exp[(VV1/2)]/k}. Each point represents the mean ± S.E.M., n = 5. Panel B, for inactivation, in the
presence of gp120, V1/2 was -38.51 mV compared with -51.64 mV in Control (Ctrl); and
V1/2 was -52.61 mV for gp120 + GSN compared with -51.14 mV for Control. Panel C, for
activation, V1/2 values for TEA sensitive currents were -41.93 mV in gp120 and -30.59 in
Control; and -31.13 mV in Gp120 + GSN group compared with -30.32 mV in Control
group. Thus, gp120 caused depolarizing shifts of the steady-state inactivation of TEA
sensitive currents and GSN can inhibit the right shift.
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3.6.

pGSN inhibition of gp120-caused Kv2.1 protein expression up-

regulation
To further characterize the mechanism of gp120-enhanced IK and its reduction by
GSN, we next examined alterations in Kv channel expression related to exposure to
gp120 and pGSN. Rat cortical neurons were first incubated for 24 h with gp120 (500 pM),
pGSN (2500 ng/ml), or gp120 and pGSN combined. The mRNA and protein levels of the
Kv channels responsible for outward K+ current in neurons, Kv1.1, Kv2.1, and Kv4.2,
were then assessed by RT-PCR and Western blot. As expected, application of pGSN
alone did not affect Kv channel mRNA expression. In comparison to control, exposure to
gp120 increased the mRNA expression of all three channel subtypes, with Kv1.1 mRNA
expression

reaching

statistical

significance

(Fig.

28A).

Consistent

with

our

electrophysiological findings, co-incubation with pGSN attenuated gp120-enhanced
expression of Kv2.1 channel mRNA, but did not affect the elevated expression of Kv1.1
and Kv4.2 mRNA (Fig. 28A). Similarly, channel protein levels were unaffected by the
application of pGSN alone, but were significantly increased for all three Kv channel
subtypes in the gp120 exposed group (Fig. 28B). Again in agreement with our
electrophysiological studies, co-incubation with pGSN was found to prevent gp120induced elevations in Kv2.1 protein level, without inhibiting similar increases in the
amount Kv1.1 and Kv4.2 protein (Fig. 28B).
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Figure 28. pGSN inhibition of gp120-induced Kv2.1 channel expression. Neuronal
cultures were treated with 500 pM gp120 with or without 2.5 μg/ml pGSN for 24 h. Band
density was analyzed by Image J and normalized by internal control. Data represents
means ± S.E.M. from 3 independent experiments. Panel A, gp120 increased the levels
of Kv1.1 mRNA expression (p < .05). Although increased levels of Kv2.1 and Kv4.2
mRNA expression did not reach the statistical significance (p < .05 compare to control),
the expression levels of Kv2.1 mRNA was down-regulated by pGSN compared to gp120
group (p < .05). Panel B, gp120 significantly increased the levels of Kv1.1, Kv2.1 and
Kv4.2 channel protein expression (p < .01). pGSN significantly reduced only Kv2.1
channel protein expression (p < .01). pGSN alone did not alter the expression levels of
Kv channels. * p < .05 vs. control; ** p < .01 vs. control; # p < .05 vs. gp120 group; ## p
<.01 vs. gp120 group.
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3.7. pGSN protected neurons from gp120-induced damage via Kv2.1
By giving that pGSN mitigates gp120-induced neuronal viability decrease, prevents
gp120-indued alterations in IK inactivation properties and Kv2.1 channel expression, we
then determined the involvement of Kv2.1 in gp120-associated neuronal apoptosis to
establish the neuroprotective activity of pGSN in gp120-associated neuronal injury by
Kv2.1. We performed studies on neuronal apoptosis and viability using gp120, pGSN,
and the Kv2.1-specific inhibitor GxTx. First, rat cortical neuron cultures were incubated
for 24 h with gp120 (500 pM), pGSN (2500 ng/ml), GxTx (12.5 or 25 nM), gp120 + pGSN,
or gp120 + GxTx. Neuronal apoptosis was then assessed by Tunel stain and neuronal
viability by MTT assay. In comparison to control, neuronal viability was reduced by 33%
in cultures incubated with gp120 (500 pM), while co-incubation treatment with pGSN
(2500 ng/ml), GxTx (12.5 nM), or GxTx (25 nM) restored neuronal viability to 88.5%,
79.0%, and 83.0%, respectively (Fig. 28A). Similarly, exposure to gp120 resulted in a 5fold increase in neuronal apoptosis, which was attenuated by GSN and GxTx in a dosedependent manner (Fig. 28B).
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Figure 29. pGSN attenuated gp120-induced neuronal damage via Kv2.1. Neurons
were exposed to gp120 (500 pM), pGSN (2.5 μg/ml), gp120 (500 pM) and pGSN (2.5
μg/ml), or heat inactivated pGSN (2.5 μg/ml) in the presence or absence co-incubated
GxTx (12.5 or 25 nM) for 24 h. Panel A, cell viability determined by MTT assay exhibited
that gp120 exposure reduced cell viability (p < .01 compare to Control), which was
attenuated by GSN or GxTx. Heat-inactivated pGSN (§) showed no protective effect.
pGSN or GxTx alone did not alter cell viability. Panel B, Left panel shows Tunel staining
results as a measure of apoptosis, with cell nuclei visualized using Dapi stain. 10 visual
fields were analyzed for each of three independent experiments. Gp120 induced
neuronal apoptosis that was attenuated by either pGSN or GxTx. These data suggest
that pGSN protects against gp120-induced neuronal damage via Kv2.1. ** p <.01 vs.
control; # p <.05 vs. gp120 group; ## p < .01 vs. gp120 group. Scale bars denote 50 μm.
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4. Discussion
In the present study, we showed that the HIV-1 envelope protein gp120 induced
cortical neuron dysfunction and apoptosis via Kv2.1. There are two novel findings: first,
pGSN performs neuroprotection in gp120-induced neuronal impairments; second, Kv2.1
is involved in gp120-mediated neurotoxicity and pGSN protection.
The main proposed mechanisms of HIV-infection and HAND are toxic substances
released from infected macrophages and microglia, including viral products such as
gp120, causing neuronal dysfunction and apoptosis [261-264]. Given the requirement for
K+ efflux in processes of programmed cell death [84], our recent research has focused
on the role of Kv channelopathies in HAND pathology [143, 144, 252, 265]. Based on
research demonstrating the protective effect of GSN against Ca2+-mediated excitotoxicity
[241, 242], combined with proteomic studies indicating the level of pGSN is decreased in
the CSF of HIV-infected individuals with cognitive impairment [243], here we delve into
the connection between gp120, pGSN, and Kv channels. Presently we show two novel
findings: first, the induction of neuronal injury by HIV-1 envelope protein gp120 entails
enhanced IK through Kv2.1 channels, and second, pGSN provides neuroprotection
against gp120 by preventing the modification of channel expression and inactivation
properties underlying IK enhancement.
Previous research into the pathways of HAND neuropathogenesis has focused
primarily on infected and/or activated mononuclear phagocyte releasing neurotoxins
including, but not limited to, arachidonic acid, platelet-activation factor, free radicals,
glutamate, quinolinate, cysteine, cytokines, amines and viral proteins (Tat and gp120).
Although neurons do not express CD4 receptor, a principal receptor for HIV-1 entry into
host cells, they do express the chemokine and HIV-1 infection co-receptors CXCR4 and
CCR5. Along with NMDA receptors, these receptors can be pathologically activated by
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aforementioned neurotoxins and viral products such as gp120, leading to alterations in
signal transduction, excitotoxic influx of Ca2+, neuronal dysfunction, and eventual
apoptosis [234-236]. While the process of apoptosis is now generally accepted to involve
excess K+ efflux regardless of cell type or initiating stimuli [84, 223], reports of Kv
channel contribution to gp120-related neuronal damage are rare. In a previous
publication, our data suggested gp120 may induce caspase-3 dependent neuronal
apoptosis by enhancing IA via CXCR4-PKC signaling [143]. Results from the present
experiment indicate gp120 exposure also leads to amplification of an IK current (Fig. 25),
which was found to be susceptible to Kv2.1-specific inhibition (Fig. 26), by provoking a
depolarizing shift in IK channel inactivation properties (Fig. 27) and an upregulation of
Kv2.1 channel expression (Fig. 28). Furthermore, the significance of this increased
Kv2.1 channel activity was demonstrated by MTT assay and Tunel staining assessments
of neuronal health, which established that gp120-induced neuronal damage could be
alleviated by Kv2.1-specific inhibition (Fig. 28). These findings are consistent with
research on hippocampal neurons demonstrating upregulation of Kv2.1 to be essential
to the induction of apoptosis under conditions of excess glutamate, the natural ligand of
NMDAR [256]. In a similar experiment, glutamate was found to act through NMDAR to
induce dephosphorylation of Kv2.1 channels and thereby alter channel function [266].
While HIV-1 infection of the CNS is associated with excess glutamate release and
impaired uptake [267], gp120 is also known to trigger NMDAR-mediated neuronal death
and thus may initiate similar apoptotic cascades [267, 268].
Neuron loss is a common feature observed in many neurodegenerative diseases. In
order to better understand the cellular milieu in which this occurs and identify practical
diagnostic markers, proteomic studies of CSF and plasma have been undertaken for
numerous conditions including HAND. Proteomic analysis revealed that pGSN was
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diminished in the CNS across varied conditions characterized by neuronal injury or
dysfunction, including Alzheimer’s disease [245], multiple sclerosis [244], and epilepsy
[246]. In HAND, pGSN is decreased in the CSF [243] and elevated in plasma [254].
Given the increased permeability of the blood brain barrier associated with HIV-1
infection, the depletion of pGSN in the CSF may have significance for neuronal health
and function, while the plasma abundance could be used as a diagnostic indicator [247].
It is important to note however, there are two isoforms of GSN, pGSN and cGSN, which
may have different roles and be present in different concentrations [269]. HIV-infected
macrophage have been found to secrete pGSN [270], which has been shown to be
involved in further recruitment of macrophage to sites of injury [271] and is present in
high concentration in the macrophage nodules of rhesus monkeys with SIV encephalitis
[270]. While this might imply high CNS pGSN levels may be detrimental, several studies
support the use of pGSN as a neuroprotective agent, for example in the treatment of
Alzheimer’s disease [245], multiple sclerosis [250], and stroke [249, 251, 272].
Interestingly, in a primary cortical neuron model of ischemic neuronal injury, the
enhanced expression of cGSN using the histone deacetylation inhibitor trichostatin A
was found to provide neuroprotection [251], perhaps indicating a means for targeting the
different isoforms for treatment. The mechanisms for these effects of GSN have yet to
be definitively characterized.
GSN is known to be regulated by micromolar Ca2+, among other factors, in its
function of modulating filament disassembly of the actin cytoskeleton [273] as part of ion
channel regulation, intracellular signaling, and apoptotic processes [274]. With regard to
cell death, the presence of pGSN mitigates common features such as mitochondrial
dysfunction, loss of membrane potential, and cytochrome C release [240]. Perhaps
relevant here, however, is evidence that pGSN may reduce the cytosolic Ca2+ overload
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resulting from exposure to excitotoxic stimuli by facilitating voltage-dependent Ca2+
channel (VDCC) and NMDA receptor channel rundown, while primary hippocampal
neurons cultured from GSN-null mice and exposed to glutamate exhibited decreased
actin filament depolymerization, increased Ca2+ influx, and amplified currents through
VDCC and NMDA receptor channels [241, 242]. In one report, GSN even directly
inhibited an HIV-1 viral protein Vpr from activating VDCC, thereby decreasing Ca2+ influx
and reducing apoptosis [275]. Despite what is known the altered concentration of pGSN
in HAND and its anti-apoptotic effects, no research has been yet undertaken to explore
the link between gp120-related neuronal damage, apoptotic Kv channel activity, and
pGSN. While GSN has been found to oppose gp120-mediated actin remodeling [276],
here we sought to determine concretely if pGSN might provide neuroprotective activity
against gp120 exposure and to make clear the pathways involved. In addition, one
report found the addition of GSN actually increased K+ channel activity in human
syncytiotrophoblasts [277]. In contrast, our results show that pGSN does indeed lessen
apoptosis in cortical neurons exposed to gp120 (Fig. 22) by suppressing the gp120associated upregulation of Kv2.1 expression (Fig. 28) and depolarizing shift of IK
inactivation properties (Fig. 27), thereby inhibiting gp120-enhanced IK (Figs. 24 and 25)
through Kv2.1 channels (Fig. 26), ultimately resulting in a reduction of gp120-induced
Kv2.1-dependent apoptosis (Fig. 28). Considered with research conducted elsewhere
and previously described, a tentative global picture emerges of the relationship between
HIV-1 gp120 exposure, apoptotic K+ efflux through Kv2.1 channels, and the protective
role of pGSN in suppressing gp120-mediated enhancement of apoptotic Kv2.1 currents.
Although the present study demonstrates that pGSN protects gp120-induced
neuronal injury via inhibition of gp120 enhancement of Kv2.1 expression and Kv2.1
current in rat cortical neuronal cultures, the exact mechanism underlying pGSN-
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mediated protection is not yet clear, nor is the site(s) of action – intracellular and/or
extracellular?

A previous study from our laboratory showed gp120 interacts with

intracellular signaling, resulting in an enhancement of outward K+ currents and
consequent neuronal injury [143]. In another study carried out on Jurkat T cells, GSN
was found to block the interaction between viral protein and voltage-gated ion channel.
These results suggest that pGSN may inhibit the interaction between gp120 and Kv2.1
leading to its neuroprotection.

Another possibility is pGSN blocks the interaction

between gp120 and Kv2.1 channel as viral proteins were found to interact with ion
channels [275]. In addition, pGSN may protect neurons through inhibition of gp120mediated activation of caspases since gp120 has been shown to induce neuronal injury
via activation of caspases [278, 279] and GSN has been reported to, in complex with
phosphatidylinositol 4, 5-biphosphate, inhibit caspase activity and retard apoptotic
progression [280].

As to the site of pGSN action, it appears that pGSN acts

extracellularly since pGSN inhibited gp120-induced shift of outward K+ current
inactivation curve shortly after brief bath perfusion of pGSN (Fig. 27). Nevertheless,
further studies are definitely needed to unravel the mechanisms of pGSN-mediated
neuroprotection and the site(s) of action.
It is worth pointing out that the effective concentrations for gp120 and GSN were
different in studies measuring cell viability and K+ current, with higher concentrations for
studying cell viability. This is because, in the same time window, higher concentrations
were needed to produce changes in cell viability in comparison with the concentrations
used to generate alterations of membrane ionic currents conducted by ion channels.
Importantly, it is difficult to form gigaohm seal and record whole-cell current from injured
cells. For these reasons, different concentrations of gp120 and GSN were employed in
the present study.
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In summarizing the present experiment, several principal findings bear mention. First,
exposure to gp120 causes neuronal injury by amplifying neuronal IK current via
modification of Kv2.1 channel expression and activation. Second, the presence of pGSN
mitigates gp120-induced apoptosis by inhibiting gp120-related enhancements of Kv2.1
channel activity. Collectively, these experimental results serve to further define the link
between HAND pathogenesis and Kv channelopathies [265], while at the same time
supporting a potentially neuroprotective role for pGSN in the treatment of HAND and
other neurodegenerative diseases.

This is a peer-reviewed article published in Molecular and Cellular Neuroscience.
Volume 57, November 2013, Pages 73–82.

135

Chapter 5
Summary and prospect
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Milder forms of HAND remain prevalent in the era of cART. Given that HIV-1 proteins
and toxic factors released from infected cells persist in brain while viral load is well
controlled in blood, there are remaining uncertain mechanisms of viral protein
neurotoxicity and increasing interests in myelin sheath loss and WM damage in
neuroHIV brain. Presently we show six novel findings: 1) HIV-1 Tat increases KV1.3
currents in oligodendrocytes by interacting with KV1.3 channel and interrupting channel
phosphorylating regulation; 2) Continuous increased K+ efflux through KV1.3 leads to
OPC and oligodendrocyte apoptosis and loss of cell viability; 3) Tat exposure decreases
MBP expression in highly purified primary rat oligodendrocyte cultures and, disturbs
myelin structures in corpus callosum and stratum of cultured brain slices; 4) Tat
treatment hinders OPC maturation in primary OPC culture; 5) In primary neuronal culture,
the induction of neuronal injury by HIV-1 envelope protein gp120 entails enhanced IK
through Kv2.1 channels; 6) pGSN provides neuroprotection against gp120 by preventing
the modification of channel expression and inactivation properties underlying IK
enhancement. Collectively, these experimental results serve to further define the link
between HAND pathogenesis and KV channelopathies, while at the same time
supporting a protective role of KV1.3 blockade for OPC/oligodendrocytes protection and
neuroprotective

role

of

pGSN

in

the

treatment

of

HAND

and

other

demyelination/neurodegenerative disease.
The axon damage and myelin injury are still challenging in therapeutic strategy of
HAND. The ways on the regulation of oligodendrocyte lineage cell development are wellestablished including the extracellular pathways, cell to cell contact, and intracellular
pathways. The strategies for promoting axonal remyelination have been introduced
especially in those demyelinating disease like multiple sclerosis, of which KV channel is
an attractive target. It is anticipated that those strategies for promoting axonal
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remyelination in other neurodegenerative disorders can be applied for HIV-1-associated
oligodendrocyte/myelin injury; thought studies are needed to elucidate the underlying
mechanisms for HIV-1-associated brain WM damage. However, further studies on
understanding the mechanisms underlying HIV-1-associated oligodendrocyte/myelin
injury may be hampered by the following potential difficulties. First, oligodendrocytes
share many common extracellular signals and intracellular signaling pathways with
neurons, the proposed “inside-out” and “outside-in” mechanisms are indistinguishable
[65]. Second, the pro-proliferation signals for OPC are generally anti-differentiation. This
will be a significant challenge to specify the certain time window to access proper
remyelination in vivo. Overall, enhancing remyelination will be an important therapeutic
strategy for HAND and other neurodegenerative disorders in the future [175].
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